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Delivering drugs to effectively treat diseases of the back of the eye can be 
a challenging task. Although pharmacological therapies exist, drug delivery 
devices and techniques are not very effective at targeting delivery of drugs to the 
diseased tissues.  This work introduces a novel approach to effectively deliver 
drugs to target tissues such as the choroid and retina. The approach involves a 
device, a hollow microneedle, to administer the drug formulation into a unique 
location in the eye, the suprachoroidal space. This new route of administration 
and a device to accomplish the delivery may provide an effective way to treat 
diseases of the choroid and retina.   
The first part of the work determines the ex-vivo feasibility of delivering 
materials within the suprachoroidal space. The results show that fluids and 
particles can be delivered into the suprachoroidal space of rabbit, pig and human 
eyes using a hollow microneedle. It further examines the important parameters 
for injection of the particles within the suprachoroidal space. The data shows that 
injection pressure and microneedle length are important parameters for effective 
delivery of particles. The results lead to a theory on the mechanism by which the 
particles are delivered into the suprachoroidal space.  
The second part of the research aims to develop a reliable in vivo delivery 
device and study the surface area coverage of materials injected into the 
suprachoroidal space.  A hollow glass microneedle device is developed and for 
the first time shown to be effective in delivering a fluid into the suprachoroidal 
space in vivo.  Up to 100 µL of India ink could be delivered into rabbit eyes in 
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vivo and the spread within the suprachoroidal space is characterized. The results 
show that a single microneedle injection can cover a significant percentage of the 
available suprachoroidal space. This is the first study to examine the spread of a 
material injected into the suprachoroidal space of a live animal. A hollow metal 
microneedle device is also developed and shown to be effective. The device was 
able to inject up to 150 µL of latex into suprachoroidal space of fresh human 
cadaver eyes. The spread of latex is characterized and the results also show that 
a significant portion of the suprachoroidal space can be covered.  
 The final part of the study examines the clearance of materials injected 
into the suprachoroidal space of rabbit eyes in vivo. First a comparison of a 
suprachoroidal injection to a conventional intravitreal injection shows that a 
suprachoroidal injection is more targeted to the chorioretinal tissues. In addition 
hollow microneedles are shown to effectively target macromolecules and a 
therapeutic antibody to the chorioretinal tissues. A study of the clearance kinetics 
show half lives within the suprachoroidal space on the order of several hours. 
Nano- and microparticles were also injected into the suprachoroidal space and 
showed very effective targeting. These non-degradable particles are shown to be 
present in the suprachoroidal space for months. Basic visual safety assessments 
identified no adverse effects from the injection of these materials. This represents 
the first study to compare intraocular clearance kinetics between a 
suprachoroidal injection and an intravitreal injection. It is also the first study to 
examine the clearance of a variety of materials from within the suprachoroidal 
space.  
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Overall this work shows that microneedles have the capability to deliver a 
variety of materials into the suprachoroidal space of rabbit, pig, and human eyes. 
The injection can be done in a minimally invasive way with the proper design of 
an injection device and can target the chorioretinal tissues more effectively than 
the currently used method. In addition particles have long residence times in the 
suprachoroidal space, so a particle based drug formulation could provide 
sustained delivery to the eye. This work represents the first comprehensive study 
on using the suprachoroidal space as a drug delivery route and also the first 










The leading causes of blindness in the industrialized world are diseases 
that affect the back of the eye (del Amo and Urtti 2008). These diseases include 
age-related macular degeneration (AMD), diabetic retinopathy and uveitis, 
among others. An increasing number of pharmacological therapies exist to 
combat these diseases, but there are limited options for delivering these drugs 
effectively to their targets in the posterior segment of the eye.  Delivering drugs to 
the posterior segment is hard primarily because of difficult access to the target 
tissues and the eye’s natural barriers that prevent foreign material from moving 
into them. The target tissues vary depending on the disease and sometimes 
even the stage of the disease, but are often the choroid and retina, as in the case 
of AMD, diabetic retinopathy and uveities (Kimura et al 2001, Zarbin and Szirth 
2007). Therefore, an effective drug delivery system targeting the back of the eye 
would provide a significant improvement in the management of these vision-
threatening diseases.  
An effective drug delivery system for the back of the eye should embody 
four general characteristics. First, it should be minimally invasive and safe, so as 
to avoid complications caused by the procedure. Second, the drug should be 
administered in such a way that it is well targeted to the desired tissues and limit 
exposure to other regions of the eye. This would allow for high bioavailability 
while reducing adverse events and toxicity in surrounding tissues. Third, it should 
be capable of sustained delivery of the drug to reduce the frequency of 
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administration and allow for better therapeutic control. Finally, administration of 
the drug should be as simple as possible, requiring only a routine office visit or, 
ideally, permitting self administration. A simple, reliable procedure can help 
reduce errors and compliance problems. Current methods of drug delivery to the 
posterior segment cannot meet all of these requirements.  
Current local posterior segment drug delivery methods can be 
characterized by two overarching strategies: periocular or intravitreal (Ghate et al 
2007, Kim et al 2007). The periocular strategy deposits a drug on the outer 
surface of the globe and either relies on diffusion, natural transport mechanisms 
of the eye or an applied biophysical driving force (e.g. iontophoresis) to deliver 
the drug inward towards its intraocular target. Periocular methods are usually 
minimally invasive, but often suffer from poor targeting, low bioavailability and 
limited sustained release capabilities. The intravitreal method involves placing 
the drug formulation directly into the vitreous of the eye; the drug can then diffuse 
outward towards the retina and choroid. This is often accomplished by an 
intravitreal injection or an implant, which introduces the drug directly into the back 
of the eye and can be designed for sustained release. However, intravitreal 
delivery is invasive, carries a risk of endophthalmitis, and often exposes 
unintended tissues to the drug.  
The research presented here aims to improve upon these two strategies 
by introducing a new approach, directly delivering drugs between and within 
tissues of the posterior segment. More specifically we believe that it would be 
advantageous to deliver drugs into the suprachoroidal space; a virtual space 
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located between the sclera and choroid layers of the globe. This would place the 
drug in direct contact with the chorioretinal surface and target the delivery to the 
diseased tissues. We further propose to accomplish the delivery using a hollow 
microneedle. Hollow microneedles, because of their size, can target the 
suprachoroidal space in a minimally invasive way. This work aims to show that 
this route of administration coupled with a microneedle device can have the 
potential to meet many of the requirements for an effective delivery device.  
The overall objectives of this research are to (1) determine the feasibility 
of a hollow microneedle to deliver into the suprachoroidal space, (2) characterize 
the spread of injected fluids within the suprachoroidal space, and (3) determine 
the clearance of materials injected into the suprachoroidal space in vivo. 
Accordingly the main body of the thesis is divided into three parts:   
 
1. Demonstrate the feasibility of a hollow microneedle to deliver fluids and 
particles into the suprachoroidal space using hollow microneedles in vitro 
and characterize the important parameters for delivery 
2. Develop an effective in vivo device to inject into the suprachoroidal space 
and characterize the spread of the injected material in the suprachoroidal 
space.  
3. Determine the in vivo clearance of small molecules, macromolecules and 
particles from within the suprachoroidal space and demonstrate effective 
targeting as compared to conventional delivery.  
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CHAPTER 2  
BACKGROUND 
 
2.1 Anatomy of the Eye 
 The eye is carefully organized to allow light transmission in order to 
provide sight. (Figure 2.1.1) The tissues and fluids that make up the eye are 
centered on this function as well as the need to keep the eye free from disease. 
The front surface of the eye is bathed with a multilayered tear film designed to 
keep the surface of the eye wet and foreign particles from remaining on the eye. 
It is slowly flowing and is drained through the nasal lachrymal duct, upon blinking. 
(Zignani et al 1995) These natural functions of the eye are key barriers 
preventing many topically applied drugs from reaching their targets in the eye. 
The cornea is essentially the transparent window in which most of the refractive 
power of the eye lies. The size and arrangement of the collagen fibers that make 
up the bulk of the cornea are the key to its transparency. It contains an 
epithelium and is divided into five layers, the bulk of which is the stroma. (Meek 
and Fullwood 2001)  
The sclera, which is considered to be the white of the eye, makes up the 
remaining periphery portion of the eye and is continuous with the corneal stroma. 
The sclera is also made up primarily of collagen fibers, but their arrangement is 
quite different than the cornea. The corneal stroma is characterized with more 
uniform collagen fibril diameters and an ultrastrustructure that is more regularly 
packed than the sclera. (Meek and Fullwood 2001) On the surface of the sclera 
is the conjunctiva which contains tiny blood vessels which are normally invisible 
but become obvious when the eye is irritated. The front portion of the eye 
(anterior segment) can be loosely defined as the portion of the eye anterior to the 
lens. This is made up of primarily the cornea, iris, pupil, aqueous humor, and 
lens. The anterior segment that holds the aqueous humor is further divided in 
anterior and posterior chambers. (Kaufman and Alm 2002) Aqueous humor is 
generated from the ciliary body and excreted into the posterior chamber and 
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eventually flows into the anterior chamber. It is drained through the trabecular 
meshwork and Schlemm’s canal. This maintenance of the flow is critical in 
controlling the intraocular pressure. (Brubaker 1982) 
 The structures behind the lens make up the posterior segment of the eye. 
The bulk of the posterior portion is made of a clear gel called the vitreous humor 
which resides in the vitreous chamber, and makes up nearly 80% of the volume 
of the eye. The vitreous bathes one of the most important layers for vision, the 
retina. The retina lines 2/3 of the circumference of the posterior eye and provides 
the photochemicals and neurological connections for processing light to the 
visual cortex and converting it into vision. The central region of the retina, located 
in the back of the eye near the optic disc, is the macula. The macula is 
approximately 1.5 mm in diameter and the center of the macula which provides 
the clearest vision is the fovea. (Kaufman and Alm 2002) 
The layer directly above the retina is the choroid. The choroid is a large 
network of blood vessels whose purpose is to provide nourishment to the 
photoreceptors present in the retina. The choroid along with the iris and ciliary 
body make up what is called the uvea. The layer above the choroid is the sclera, 
whose primary purpose is structural. It provides the housing for the contents of 
the eye and a protective function. The densely packed collagen fibers that make 
up the sclera play an important role in this function. The sclera is hydrated and its 
elastic nature allows for deformation of the tissue without being punctured. (Lens 




Figure 2.1.1 Image of the anatomy of the eye highlighting the major tissues. 
Image of the eye was adapted from National Eye Institute, National Institutes of 
Health, with permission. 
 
One important region of the eye to highlight is the suprachoroidal space. 
The suprachoroidal space is a virtual space in the eye that becomes evident 
when there is fluid buildup between the sclera and choroid layers of the eye (Emi 
et al 1989, Krohn and Bertelsen 1997). Figure 2.1.2 shows the location of this 
region within the eye. This region is particularly attractive because it can 
accommodate a fluid and it is adjacent to the choroid and retina. These two 
tissues are the targets for many diseases such as age related macular 
degeneration, uveitis, and diabetic retinopathy which lead to blindness. The 
suprachoroidal space is often associated with the drainage of aqueous humor 
from the anterior portion as it is part of the uveoscleral outflow system (Krohn 
2004). It is most often relevant in cases where there is fluid buildup in the 
suprachoroidal space as a result of complications from vitreoretinal surgery. In 
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standard cases the fluid is drained from the eye naturally and the choroid and 
retinal layers return back to their original position. In severe cases a choroidal 
hemorrhage may develop and surgical intervention may be necessary. (Healey et 
al 2007)  
 
 
Figure 2.1.2 The suprachoroidal space is located between two posterior tissues, 
the sclera and choroid. This region expands when there is a buildup of fluid 
between these two layers to form the suprachoroidal space. Image of the eye 




2.2 Eye Diseases 
 
2.2.1 Introduction  
 Blindness and low vision are significant impairments affecting the adult 
population. One in 28 Americans over the age of 40 suffers from some sort of 
visual impairment. The prevalence rates of visual impairment increase with age 
and because of an increasing elderly population, effective treatment of these 
diseases is a growing need. The most common diseases that cause visual loss 
are age related macular degeneration (AMD), glaucoma, diabetic retinopathy, 
and cataract formation (Congdon et al 2004). Below is a summary of these 
diseases and their treatment modalities.  
 
2.2.2 Glaucoma  
Glaucoma is a disease that occurs when there is a disruption in the 
production and/or drainage of aqueous humor in the eye. The aqueous humor is 
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in the anterior portion of the eye and is produced by the ciliary body. (Lee and 
Higginbotham 2005) The fluid flows around the iris and through the pupil into the 
anterior chamber and out through drainage canals located in the trabecular 
meshwork. When either too much fluid is produced or not enough is drained, the 
buildup causes the internal pressure in the eye to become elevated. As a result, 
glaucoma is marked by an increase in eye pressure. If this imbalance goes 
untreated, vision will be negatively impacted. (Brubaker 1982) 
There are various medications for glaucoma aimed at controlling the fluid 
flow and most come in the form of topically applied drops. The target for many of 
the drugs lies in the area of drainage of the aqueous humor (trabecular 
meshwork) or the production of the aqueous humor (ciliary body). (Alward 1998) 
The flow and pressure must be maintained at a normal level at all times in the 
eye and so ideally drug concentrations should be maintained at a therapeutic 
level in these areas for an extended period of time. Unfortunately topical eye 
drops are currently the standard method of delivery of medication and usually 
require a dosing regimen of multiple times a day. (Lee and Higginbotham 2005) 
This can often lead to non-compliance and poor management of intraocular 
pressure. When medications are not able to control this, surgery may be 
necessary. (Clement and Goldberg 2011) Inadequate control of glaucoma over a 
long period of time can have serious consequences to vision. The pressure has 
an impact on all the tissues in the eye and is a major cause of optic nerve 
damage. The need for proper management of glaucoma is immediate as it is one 
of the leading causes of blindness in United States. (Wax et al 2002)  
 
2.2.3 Age Related Macular Degeneration (AMD) 
Age related macular degeneration is a disease that affects the central part 
of the retina, the macula. Light is focused onto this region of the retina and 
provides central vision. Any alteration to the macula is detrimental to central field 
of vision.  ARMD is separated into two types: wet and dry. The wet form occurs 
when blood vessels leak near the macula and scarring develops altering the 
macula and preventing clear vision. Dry AMD occurs when cells of the retina 
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begin to die and the retina begins to thin.  Unfortunately no therapy is available 
for the dry form of ARMD, however the wet form usually involves the use of laser 
therapy to prevent blood leakage into the retina.  Intravitreal injections can also 
be made to target the drug towards the retina. Current research involves looking 
at a variety of drugs to combat the growth and leakage of blood vessels. (Ozkiris 
and Erkilic 2005)  
Pegaptanib sodium, which is marketed as Macugen® was the first drug to 
be approved for intravitreal injection for the treatment of ARMD. Clinical trials 
have showed effectiveness of the aptamer at preventing further degradation of 
vision as compared to a sham. (Fattal and Bochot 2006) Since then other anti-
VEGF drugs have gained attention. Most notably is ranibizumab, or Lucentis®, 
which was approved in 2006 for AMD. This is a humanized antibody fragment 
specifically designed for ocular therapy. Though not approved for ocular therapy, 
the complete human antibody has also gained interest. Bevacizumab , or 
Avastin®, is cheaper and doctors have been looking to it as an alternative to the 
more expensive therapy of Lucentis. (Steinbrook 2006)  
Other drugs include corticosteroids such as triamcinolone acetonide. 
(Myles et al 2005)  Choroidal neovascularization also develops in many patients 
with wet ARMD. Here blood vessel growth in the choroid becomes abnormal and 
penetration of blood vessels into the retinal space causes vision impairment. The 
targets for many of the drugs that are prescribed for these conditions are the 
choroid and retina which are in the posterior portion of the eye. (Kimura et al 
2001) 
 
2.2.4 Diabetic Retinopathy 
 Diabetic retinopathy causes damage to the retina as a result of diabetes. 
High sugar levels in the blood cause changes in the blood vessels in the retina 
which either leak (non-proliferative diabetic retinopathy) or cause abnormal 
growth (proliferative diabetic retinopathy). Both forms of the disease have the 
potential to cause total blindness and because the number of people with 
diabetes is on the rise, there is a need for effective treatment of this disease. 
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(Ockrim and Yorston 2010) Almost half of the world’s diabetic population has 
some degree of diabetic retinopathy. Among those, diabetic macular edemea is 
the leading cause of blindness. Current treatment involves the use of laser 
therapy or a surgical procedure called vitrectomy. These are usually performed 
well after the establishment of diabetic retinopathy and, as a result, earlier 
treatment with medication is desired. (Mohamed et al 2007) 
Research involving the use of antiangiogenics, steroids and 
neuroprotectants is underway and an effective delivery method may play an 
important role in the success of these medicines. Many of the drugs used are 
similar to those for AMD. Current studies with small populations involve 
intravitreal injections occurring every month for a period of six months or as 
necessary. Follow up and maintenance is a key to controlling the extent of the 
disease. A minimally invasive delivery method would allow for flexibility in dosing 
regimen as individual response to the drug may vary and will depend on the 
current extent of the disease. (Hughes et al 2005, Avery et al 2006, Chun et al 
2006) 
 
2.3 Ocular Drug Delivery Methods 
 
2.3.1 Introduction 
The eye is an intricate organ that can develop diseases that impact 
various structures or functions of the eye. As a result, drugs need to reach 
different portions of the eye depending on the disease and the mechanism of 
action of the drug. An effective drug delivery system for the back of the eye 
should embody four general characteristics. First, it should be minimally invasive 
and safe, so as to avoid complications caused by the procedure. Second, the 
drug should be administered in such a way that it is well targeted to the desired 
tissues and limit exposure to other regions of the eye. This would allow for high 
bioavailability while reducing adverse events and toxicity in surrounding tissues. 
Third, it should be capable of sustained delivery of the drug to reduce the 
frequency of administration and allow for better therapeutic control. Finally, 
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administration of the drug should be as simple as possible, requiring only a 
routine office visit or, ideally, permitting self administration. A simple, reliable 
procedure can help reduce errors and compliance problems. Current methods of 
drug delivery to the posterior segment cannot meet all of these requirements. 
Below is a short review of ocular delivery practices and current research aimed at 
increasing the effectiveness of these methods/technologies. Figure 2.3.1 shows 
some local ocular drug delivery methods for the back of the eye that are either 




Figure 2.3.1 Local drug delivery methods to the back of the eye. There are a 
variety of ways to locally deliver drugs to the back of the eye. Some of these 
approaches are highlighted above: (a, b) topical, (c, j) injections, (d, g, h, i) 
implants, and (e, f) microneedles. (Edelhauser et al 2010)  
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2.3.2 Systemic  
 Systemic administration of drugs is one of the easiest ways to deliver a 
drug to the body. However, this method provides little room for targeting the drug 
to a specific region of the body. As a result, for targeted delivery to regions of the 
eye, systemic administration can be considered ineffective. Systemic 
administration often requires high doses of the drug to be taken and side effects 
are more common as tissues other than the eye will be exposed to the drug. In 
addition toxicity concerns can arise from periodic systemic administration as a 
drug may accumulate in an undesired part of the body. For example, carboplatin 
is a drug administered systemically for treatment of retinoblastoma. The target is 
in the eye, however the drug has a tendency to accumulate in other tissues in the 
body, raising toxicity issues. Often in systemic administration, more of the drug 
will reach unwanted areas of the body as opposed to the desired target. (Myles 
et al 2005)  
A drug administered systemically has potential to reach the anterior 
portion of the eye through leaky vessels in the ciliary body. The drug can then 
diffuse through the iris and into the aqueous humor. Hydrophilic drugs are more 
likely to diffuse across the blood-aqueous barrier and reach the anterior chamber 
whereas lipophilic drugs are more likely to reach the posterior chamber of the 
aqueous humor. (Gaudana et al 2010) 
Access to the posterior of the eye is limited by the blood-retinal barrier. 
Lipophilic molecules have some ability to move across both the outer and inner 
blood-retinal barriers. Examples include chloramphenicol and benzyl penicillin, 
which have been shown to achieve appreciable levels within the aqueous humor 
after systemic delivery. The tight junctions of the blood-retinal barrier prohibit 
much of the paracelluar transport that hydrophilic drugs rely upon. As a result 
hydrophilic drugs have little chance to reach the vitreous humor of the eye after 
systemic delivery without some active transport mechanism existing within the 
eye. (Hughes et al 2005) 
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2.3.3 Extraocular Approaches 
 
2.3.3.1 Topical 
 One of the most common local methods of delivering a drug into the eye is 
to simply apply it topically, i.e. directly onto the surface of the eye. Topical 
application of the drug is often used because it is a noninvasive, convenient 
procedure and the surface of the eye is easily accessible. Topical administration 
of drugs on the surface of the eye has been around since the late 1800’s in part 
because the method is fairly simple and can be performed by most patients 
without supervision.  (Koevary 2003) However, there are many barriers 
preventing a drug that is applied to the surface of the eye from reaching the inner 
components of the eye. The natural reflex of blinking washes away much of the 
applied formulation from the surface of the eye. Tear flow on the surface of the 
eye also contributes to the removal of the drug from the eye surface. As a result, 
the drug formulation is rapidly eliminated through the nasolacrimal drainage 
system or simply from spilling out onto the face. In most cases little drug remains 
on the surface of the eye from a typical eye drop five minutes after application. 
(Eljarrat-Binstock et al 2010) The tear fluid itself is a dual layer system with an 
outer lipid layer and an inner aqueous-mucin layer. The mucin layer prevents 
many foreign particles from adhering to the surface of the eye to prevent infection 
and keep the vision pathway unobstructed. Unfortunately, from a drug delivery 
standpoint, this is a disadvantage because this means that drugs will not be able 
to reside on the surface of the eye for very long and frequent or multiple 
administration of drops is often necessary. (Koevary 2003) 
Any amount of drug that is able to remain on the surface of the eye must 
then penetrate further into the eye by diffusing across the cornea and/or 
conjunctiva. A drug that penetrates through the corneal pathway can then reach 
the aqueous humor and be able to reach targets that are in the anterior portion of 
the eye. The cornea is however, composed of multiple layers and their barrier 
properties limit permeability of many compounds across its thickness. (Jarvinen 
et al 1995) This is particularly true for hydrophilic drugs. The conjunctiva, though, 
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may allow for higher permeability of these hydrophilic drugs as the tight junctions 
in the conjunctiva are not as tight as the cornea. Unfortunately many drugs get 
absorbed by the vasculature in the conjunctiva and the drug gets taken into 
systemic circulation. The bioavailability of drugs is not just dependant on the 
ability of the drug to reside on the surface but also dependant on the drug’s 
ability to diffuse across these surface tissues. Various other barriers exist, 
preventing many drugs from reaching therapeutic concentrations further along 
the vision pathway. The combination of these barriers result on average to less 
than five percent ocular absorption of a drug applied in this manner. Practically 
speaking, topical drug delivery is then only effective for delivering drugs to the 
anterior portion of the eye.  (Jarvinen et al 1995, Koevary 2003) 
Current research in topical drug delivery has been aimed at countering the 
eye’s barriers and increase the bioavailability of topically applied drugs. These 
efforts are aimed primarily at either increasing the permeability of the drug across 
the cornea or increasing the residence time of the drug.  
Increasing permeability across the cornea can be done by adding 
penetration enhancers to the topically applied formulation. One class of 
penetration enhancers alters the structure of the cornea to allow for greater 
penetration of the drug. Examples include azone (laurocapam), hexamethylene 
lauramide, hexa-methylene octanamide, and decylmethyl sulfoxide. Use of these 
enhancers should however be done in caution as they can often cause irritation 
and permanent damage to the cornea can develop. Repeated use, from frequent 
application, can also lead to toxic levels of the enhancer with the eye. (Kaur and 
Kanwar 2002)  
An alternative approach has been to increase the solubility of the drug at 
the cornea surface through the use of cyclodextrins. (Loftssona and Jarvinen 
1999) Cyclodextrins increase the water solubility of lipophilic drugs providing a 
more stable environment in the tear film and are also shown to decrease 
irritation. Cyclodextrins have been shown to increase the permeability of steroids 
such as dexamethasone and hydrocortisone in addition to carbonic anhydrase 
inhibitors and cyclosporins when co-administered in a topical formulation. 
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Cyclodextrins may act as true carriers of lipophilic molecules in the hydrophilic 
tear film; i.e. they increase the amount of drug available at the tear film-corneal 
epithelium interface without actually causing any disruption of the corneal 
epithelium. (Loftssona and Jarvinen 1999, Stefansson and Loftsson 2002) 
Another approach to increase absorption of topically applied drugs is to 
increase the residence time of the drug on the corneal surface. A formulation 
applied to the surface of the eye that has a high viscosity will not easily be 
washed away and thus will reside on the surface of the eye longer than 
traditional drops. This would allow more time for a drug to penetrate. (Kaur and 
Kanwar 2002) High viscosity solutions, however, can be hard to apply and may 
cause increased blinking and irritation, decreasing their effectiveness. Recently, 
formulations that can gel in-situ, i.e. form viscous gels upon application to the 
eye, are of interest. Gelling can be activated by the pH, temperature, or 
electrolytes present on the surface. (Ludwig 2005) These are advantageous 
because they can be easily administered and have minimal side-effects. (Zignani 
et al 1995) Products currently utilize the enhanced viscosity and in-situ gelling 
concepts are currently available. (Saettone and Salminen 1995)  
An alternative way to increase the residence time is to use films or inserts. 
These can be placed on the surface of the eye to provide constant contact 
without being washed away. Films can come in the form of contact lenses with 
drugs loaded inside that can be released to the surface of the eye or drugs 
trapped between the lens and the surface of the eye. This introduces some 
versatility in design and can lead to a variety of sustained release scenarios. 
Inserts can be designed to sit under the lower eye-lid, so as not to obstruct vision 
and allow constant contact with the surface of the eye. However, films and 
inserts may not be properly applied by patients such as the elderly and may also 
result in non compliance. In addition continual use may introduce complications 
to the surface of the cornea. (Saettone and Salminen 1995) 
 
2.3.3.2 Iontophoresis  
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Ocular iontophoresis has become a popular research area to combat the 
poor bioavailability of topically applied drugs. The basic idea is to apply a drug 
topically to the surface of the eye and hold it there using a cup like device while 
applying an electric field across the surface tissues, which is usually the cornea 
or conjunctiva/sclera. Iontophoresis can enhance transport using any of three 
possible mechanisms: electrophoresis, electroosmosis, and electroporation. The 
main attraction to this approach is that it is minimally invasive and locally applied. 
However high current densities may cause tissue damage. The development of a 
proper formulation is important for iontophoresis to be effective. Two commercial 
products have been developed with formulations specific to iontophoresis 
application to the eye: Ocuphor (Iomed Inc.) and Visulex (Aciont Inc).  A variety 
of drugs have been tested for this delivery method including antibiotics, 
corticosteroids, and nanoparticles. (Eljarrat-Binstock et al 2010) 
 
2.3.3.3 Periocular Routes 
 Periocular delivery usually refers to delivery into the eye across peripheral 
tissues of the eye. An injection can be one method of delivering periocularly. 
There are several different types of periocular injections, but the term refers in 
general to injection where the delivery site is on the periphery of the eye. 
Common periocular injections include posterior sub-tenon, retrobulbar, 
subconjunctival, and peribulbar. A sub-tenon or subconjunctival injection involves 
injecting in the sub-tenon space or just under the conjunctiva. Retrobulbar 
injections require injecting behind the eye, near the optic nerve. This is a fairly 
invasive procedure and requires inserting the needle fairly deep in order to reach 
the posterior of the eye. Peribulbar injections are injections that occur on the 
periphery of the eye and are similar to sub-tenon injections, except the delivery is 
not specific to the tenon space. The use of these injections is not a common way 
to deliver drugs to the body. Instead they find their use in specific cases. As an 
example, retrobulbar and periocular injections are often used for ocular 
anesthesia prior to surgery. (Raghava et al 2004, Lai et al 2005) 
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 Periocular delivery can also occur with implants. The implanted device 
must be attached onto or through the periocular surface of the eye. The primary 
advantage of these systems is sustained delivery for an extended period of time. 
The drug release rate controlling material is often polymeric and these can be 
divided into degradable or non-degradable. Degradable implants offer the 
advantage of not having to go through a removal procedure. On the other hand, 
non-degradable implants offer better control of the release rate of the drug. Thin 
implants can be placed just under the surface of the eye between the conjunctiva 
and sclera. (Felt-Baeyens et al 2006) Implants can also be made to penetrate 
across the ocular tissues into the vitreous and deliver drugs directly into the 
vitreous. These implants are often placed on the surface of the sclera and so 
transport across the sclera and into the choroid and retina become important in 
determining the effectiveness of the implant. (Kuppermann 2007)  
 
2.3.4 Intraocular  
Even with these advancements, drugs applied topically exhibit very little 
absorption for drug delivery to the back of the eye. Many diseases affect the 
retina, choroid, macula, and other regions that are in the posterior portion of the 
eye.  To treat these areas, the aforementioned delivery methods are usually 
ineffective and not targeted for this purpose. As a result intraocular approaches, 
approaches that try to place the drug directly within the eye, can be more efficient 
at getting drugs to intraocular tissues. Provided below are examples of methods 
specifically motivated at delivering drugs to areas in the posterior portion of the 
eye.  
 
2.3.4.1 Intravitreal Injection 
 Intravitreal (IVT) injection is one of the most direct ways to deliver a drug 
to the posterior portion of the eye. The first reported use of an intravitreal 
injection was as early as 1911. Air was injected as an attempt to decrease the 
potential of retinal detachment. Injection of a pharmaceutically active compound 
however, took some time to come into practice. It wasn’t until the late 1970’s and 
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1980’s that drugs were being tested on an individual basis in humans. Not until 
1998 was a drug approved by the Food and Drug Administration (FDA) 
specifically for intravitreal injection. This drug was fomivirsen sodium used to 
treat cytomegalovirus and represented a breakthrough for this delivery method. 
(Jager et al 2004)  
Currently IVT injections are being used for the treatment of AMD with the 
injection of Macugen, Avastin, and Lucentis. The procedure involves only local 
anesthesia such as lidocaine. The injection is performed with a 27 or 30 gauge 
needle approximately 3 mm from the limbus (i.e. where the cornea meets the 
sclera). The needle is inserted until it penetrates into the vitreous chamber, a 
small volume is injected into the vitreous and the needle is then retracted. The 
injected volume can range anywhere between 20-100 µL. (Maurice 2001, Avery 
et al 2006) Since the injection involves penetrating several tissues before 
reaching the vitreous and the injection of a relatively large volume of fluid into the 
eye, it is not without risks. The two most important safety concerns from IVT 
injections are the actual injection procedure and the toxicity of the drug in the 
vitreous. Ophthalmologists were reluctant at first to use this procedure for exactly 
these reasons. (Peyman and Ganiban 1995)  It is also important to separate 
these two factors from each other when patients develop retinal detachment or 
endophthalmitis post injection.  
A review of IVT injections was performed by Jager et. al. in an effort to 
determine how serious these risks are to the patient. They discovered by 
examining 14,866 IVT injections over 4,382 eyes resulted in a prevalence of 
endophthalmitis at a rate of 0.3% per injection and 0.9% per eye. Other 
complications such as retinal detachment, iritis, cataract formation, etc. were 
more commonly associated with the drug rather than the actual injection method. 
Nevertheless they caution that it is very important that the proper technique be 
followed because when complications do arise from this delivery method, they 
may lead to permanent vision loss. (Jager et al 2004) It is important to note, 
however, that the per eye rate is higher than the per injection rate, indicating that 
when multiple injections are necessary, the risks to damage can rise 
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considerably for any given patient. Since it is not uncommon to have monthly 
injections of the above mentioned drugs, one can imagine the risks for 
complications can become a serious concern and long term delivery by this 
method can prove to be dangerous.  
 
2.3.4.2 Intravitreal Implants 
In an effort to provide controlled or sustained release to the back of the 
eye, much of the research has focused on designing implants that release drug 
into the vitreous. A number of commercial products have recently been marketed 
that can provide drug delivery for a period of weeks to months. Examples include 
Medidur, Vitrasert, Retisert, Ozurdex (formerly Posurdex) etc. Many of these 
products are implants that are placed either directly in the vitreous or attached to 
the globe so that the drug formulation is released into the vitreous (Lee et al 
2010, Yasukawa and Ogura 2010). These implants have shown well controlled 
release kinetics in-vitro and in some cases in animal models as well. Implants 
such as Medidur, Vitrasert and Retisert are nonbiodegradable and have to be 
removed once the drug formulation has been fully released from the device. 
Osurdex is a biodegradable implant that does not have to be removed at the end 
of the release of the drug (Kane et al 2008, Chang-Lin et al 2010, Kuno and Fujii 
2010).   
 
2.3.4.3 Suprachoroidal Delivery 
In the past few years researchers have begun to explore administration 
into the suprachoroidal space. The first group of researchers to look at the 
suprachoroidal space from a drug delivery perspective showed that a transparent 
viscous gel made from a polymer, polyorthoester (POE), could be injected into 
the suprachoroidal space of pigmented rabbits. They examined the safety of their 
‘tunneling’ procedure and of the POE in the space. The POE was present in the 
space for up to 3 weeks and the procedure and the material was well tolerated by 
the rabbits  (Einmahl et al 2002). Others have shown that the space can be 
accessed by constantly infusing into the sclera. A commercially available 
 20
magnetic resonance imaging (MRI) contrast agent, Magnevist®, was infused into 
the eye. Magnevist consists of a Gd-DTPA which is a soluble gadolinium 
complex of diethylenetriamine pentaacetic acid of approximately 1 kDa in size.  
Magnetic resonance imaging  imaging of Intrascleral infusions of Gd-DTPA  
showed that Gd-DTPA  accumulated in the suprachoroidal space and was 
cleared within hours. (Kim et al 2007)  
More recently a cannulation device has been developed that can be 
inserted into the suprachoroidal space after an incision into the sclera is made. 
The long cannula can be inserted from the site and slid to a more posterior site 
after which an injection can be made to deliver a formulation into the 
suprachoroidal space (Olsen et al 2006). Sustained release implants have also 
be inserted just underneath the sclera into horses to show treatment of uveitis for 
periods of up to 2 years. Sustained delivery of cyclosporine to suprachoroidal 
space showed drastic improvement in the visual acuity of the horses with minimal 
side effects, demonstrating the potential for treatment of choroidal and retinal 
diseases. (Gilger et al 2006)  
 
2.4 Microneedles and Their Applications in Drug Delivery 
 
2.4.1 Introduction 
The term microneedle does not represent a singular device or design of a 
needle but is instead a term used to describe a class of micrometer scale 
needles that can be used in a variety of ways to deliver drugs locally to the body. 
Microneedles can be made from a variety of materials, such as metals, glass and 
plastics and they can be designed in various shapes. However, the overall 
purpose of all microneedles remains similar: microneedles pierce into a tissue to 
create micron scale pores or channels through which therapeutics can be 
transported more effectively into the body than without such pores or channels. 
We present in this section four general approaches to using various types of 
microneedles to deliver molecules into tissues.  Microneedles were first 
envisioned for application to the skin and as a result many of these strategies 
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were developed with the skin in mind. However all of these approaches are 
applicable to the eye and may be advantageous depending on the target tissue 
and necessary delivery requirements. A summary of the approaches in a 
graphical format is shown in Figure 2.4.1 (Arora et al 2008).  
 
 
Figure 2.4.1 Microneedle strategies for drug delivery into tissues. (a) Poke and 
apply: Insert microneedles into the tissue to form pores, remove microneedles 
and then apply the drug formulation to the surface of the tissue. (b) Coat and 
poke: Coat microneedles with a drug formulation, insert microneedles into a 
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tissue to dissolve off the coating formulation within the tissue and remove 
microneedles to leave the deposited drug in the tissue. (c) Poke and release: 
Encapsulate drug in a biodegradable microneedle, insert microneedles into the 
tissue and leave them there, and as the microneedle degrades the drug is 
released into the surrounding tissue. (d) Poke and flow: Insert a hollow 
microneedle into a tissue, apply pressure to the fluid in the microneedle to flow 
the fluid into the tissue, and remove hollow microneedle after the desired volume 
has been injection, leaving behind fluid in the tissue. Adapted from Arora et al 
2008. 
 
2.4.2 Poke and Apply 
One microneedle strategy is to simply insert solid microneedles into a 
tissue and remove the microneedles leaving behind channels or pores that make 
the tissue more permeable. A therapeutic agent can then be applied to the 
surface of the microneedle treated tissue. This makes the delivery a two step 
procedure; the first step is the creation of the channels followed by a second 
application of the formulation to be delivered.  With this approach the 
microneedles serve primarily to create a transport pathway and do not come into 
contact with the drug formulation.  
One of the first reported studies showed that microneedles made of silicon 
using microfabrication technologies borrowed from the microelectronics industry 
showed that holes created by microneedles could increase the permeability of 
human epidermis to calcein by four to five orders of magnitude (Henry et al 
1999). Additional experiments using a similar strategy showed that pores created 
by microneedle could increase the permeability of larger compounds such as 
insulin, bovine serum albumin (BSA), vaccines and nanospheres up to 50 nm in 
radius (McAllister et al 2003, Martanto et al 2004, Ding et al 2009). Many of these 
early studies showed that microneedles could create pores to enhance the 
delivery of many compounds that would otherwise not be deliverable through the 
skin.  
This strategy can be applied to the ocular tissues as well. Solid 
microneedles can be inserted into tissues such as the sclera, cornea, near the 
limbus, or near the target area and removed after creating pores.   Solid 
microneedles have been shown to pierce the sclera tissue and create pores 
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within the sclera (Jiang et al 2007). Topical drops could then be applied to the 
surface of the eye. The pores would allow enhanced diffusion of the applied 
molecule and increase the bioavailability of the drug. However, unlike the skin, 
the residence time of most topical applications is on the order seconds to 
minutes (Zignani et al 1995). The short contact time makes this approach less 
advantageous.   
 
2.4.3 Coat and Poke  
A strategy that makes the delivery process a single step procedure is the 
coat-and-poke approach. This approach requires the drug formulation to be 
coated on the surface of a microneedle. Upon insertion of the coated 
microneedle into a wet tissue, the coating formulation dissolves off of the 
microneedle and the microneedle can be removed, leaving the coating 
formulation inside the tissue within the channels created by the microneedle. This 
allows for the drug to be localized just at the insertion site.  Coated microneedles 
can provide targeted delivery to tissues such as the sclera, cornea, or any part of 
the eye that can be accessed directly for the exterior of the eye. This can be 
done with individual microneedle insertions or an array of microneedles inserted 
simultaneously into the desired tissue.  
The cornea is often treated as a barrier to drug delivery. This is especially 
true when glaucoma is treated using drops on the surface of the eye and the 
drug needs to be delivered to tissues further within the eye. However, if drugs 
can be delivered directly to the corneal stroma, i.e., intrastromal delivery, it can 
be used advantageously for drug delivery. The approach is to coat the surface of 
the solid microneedle with a model compound, insert it into the wet cornea 
environment, allow the coating to dissolve off of the microneedle and then 
remove the microneedle leaving most of the coated formulation within the 
cornea. Figure 2.4.2 shows a solid stainless steel microneedle before and after a 
coating of a dye, sulforhodamine.  
To test this approach, sodium fluorescein was used as a model molecule 
and coated on the microneedle. Jiang et al (2007) studied the intraocular 
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distribution of sodium fluorescein after intrastormal delivery using coated 
microneedles and showed that this held true.  The work showed that 
microneedles can indeed deliver molecules directly within the corneal stroma in 
vivo in rabbits. A single solid stainless steel microneedle was coated with 280 ng 
of sodium fluorescein. The microneedle was inserted into the cornea and the 
concentration in the cornea, aqueous humor and lens was measured over time in 
vivo. As a comparison, experiments were also done applying a 3 µg dose of 
sodium fluorescein topically to the surface of the rabbit eye as a drop and 
identical measurements were made. (Jiang et al 2007) 
 
 
Figure 2.4.2 (a) A brightfield image of a single solid stainless steel microneedle. 
The surface of the microneedle can be coated with a liquid formulation. (b) As 
an example, it can be coated with an aqueous formulation of sulforhodamine B 
(red liquid). Scale bar: 500 µm   
 
The coated microneedle experiment showed that microneedles could be 
inserted into the cornea and that sodium fluorescein dissolves off the needle 
creating a depot within the stroma. In addition, sodium fluorescein levels in the 
anterior ocular tissues were higher than a topical application of an equivalent 
dose. As an example at the three hour time point, fluorescein concentrations in 
the eye were about 60 times higher than a topical application of an equivalent 
dose. The kinetic data also demonstrated that microneedle based administration 
of fluorescein resulted in extended residence time of fluorescein as compared to 
topical application. In both cases fluorescein concentrations returned to near 
baseline levels in the anterior segment within 24 hours. The calculated 
bioavailability of coated sodium fluorescein delivered to the eye was 69 % with 
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microneedle administration versus only 1 % for topical administration (Jiang et al 
2007). This shows that microneedle administration effectively targeted the cornea 
while the topical application resulted in nearly all of the fluorescein being washed 
away from the eye.  
These results indicate that coated microneedles should be able to deliver 
a therapeutically relevant molecule to the cornea and anterior segment of the eye 
more effectively than topical administration. Furthermore, the targeting capability 
of microneedles should allow for a high bioavailability of the drug and an 
enhanced pharmacological effect. In order to test this pilocarpine, a drug used to 
treat glaucoma, was delivered intrastromally using microneedles. Solid stainless 
steel microneedles were coated with approximately 1.1 µg of pilocarpine and 
inserted in the peripheral cornea of New Zealand white rabbits in vivo (Jiang et al 
2007). Microneedle based administration of pilocarpine caused the pupil to 
constrict 2.5 mm within 15 minutes after insertion. A similar dose of pilocarpine, 5 
µg, delivered topically cause constriction of only 1 mm. Additionally the pupil 
began to constrict several minutes earlier when pilocaprine was administered 
using microneedles. This indicated that the kinetics of microneedle based 
delivery of pilocarpine is faster than topical. When 500 µg of pilocarpine were 
applied topically, the pupil constricted a total of 4 mm with kinetics similar to that 
of 5.5 µg administered using coated microneedles. These experiments showed 
that a drug can be administered using microneedles and can be targeted by 
inserting the microneedles within the peripheral cornea (Jiang et al 2007). 
This approach relies heavily on the ability to coat a drug on the solid 
microneedle. As a result the coating formulation plays an important role in 
obtaining a sufficient amount of drug on a microneedle and having consistent 
coatings. In experiments studying the aqueous coating of riboflavin it has been 
shown that the viscosity and surface tension of the coating formulation are two 
critical parameters. Optimization of the viscosity enhancing agent, CMC, and the 
surfactant, Lutrol F-68, in the coating solution revealed that uniform and 
repeatable coatings were achievable (Gill and Prausnitz 2007aa). The coatings 
were performed using a micro-dip coating procedure that confined the coating to 
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the microneedle and prevented the substrate from being coated (Gill and 
Prausnitz 2007b). To confirm this, sulforhodamine was coated onto microneedles 
using sucrose and Tween 20 as a viscosity enhancer and surfactant respectively. 
Addition of sucrose to the coating solution increased the thickness of the coating 
and adding Tween 20 increased the uniformity of the coating. Further work 
showed that non-aqueous coating formulations can also be applied to 
microneedles in a similar fashion. However, if solvents, such as ethanol, have 
low surface tension, then a surfactant may not be necessary (Gill and Prausnitz 
2007aa). 
A variety of materials can be coated onto microneedles These range from 
small molecules, to large proteins, and even microparticles (Xie et al 2005, Gill 
and Prausnitz 2007b).  Figure 2.4.3 shows the coating of calcein, vitamin B, 
bovine serum albumin, plasmid DNA, viruses, and latex microparticles onto solid 
microneedles (Gill and Prausnitz 2007b). Demopressin, a synthetic peptide 
hormone, has also been coated onto titanium microneedles (Cormier et al 2004).  
The ability to coat a wide array of molecules makes this attractive for drug 
delivery to the eye. Many ophthalmological drugs could be coated onto 
microneedles and delivered in this fashion for targeted delivery. Pilocarpine has 
been effectively delivered in this fashion within the stroma of the cornea, but 
many other drugs could similarly be coated and delivered  (Jiang et al 2007). The 
key to this approach would be to coat a sufficient amount of drug on a 
microneedle or small array of microneedles to provide a therapeutic benefit.  
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Figure 2.4.3 Brightfield and fluorescent images showing the variety of materials 
that can be coated onto solid stainless steel microneedles: (a) calcein, (b) vitamin 
B, (c) bovine serum albumin conjugated with Texas Red, (d) plasmid DNA 
conjugated with YOYO-1, (e) modified vaccinia virus - Ankara conjugated with 
YOYO-1, (f) 1-μm diameter barium sulfate particles and (g) 10-μm diameter latex 
particles. Scale bar: 200 μm. Adapted from Gill and Prausnitz 2007b.  
 
2.4.4 Poke and Release  
Instead of inserting a microneedle, depositing the drug and removing the 
microneedle, the microneedle itself could be left in the tissue. This approach, the 
poke-and-release approach, involves loading a drug formulation within a 
microneedle and leaving the microneedle in the tissue as it releases the loaded 
drug formulation into the tissue. These microneedles are usually made of 
biodegradable polymers or sugars that encapsulate a drug and as the polymer 
breaks down or sugar dissolves it releases the active within the tissue. The 
added benefit of this approach is that the polymer could control the release of the 
molecule that is encapsulated within the microneedle and provide sustained 
release. This would extend the time the drug is within the eye and allow for less 
frequent administration.   
Microneedles made of biodegradable polymers have been shown to 
successfully insert and deliver molecules into the skin. Park et. al (2005) showed 
that an array of polymer microneedles can be fabricated using a micromolding 
technique. Mechanical testing of these microneedles made of biodegradable 
polylactic and polyglycolic acid copolymers (PLGA) were strong enough to insert 
into the skin and increase skin permeability of calcein and bovine serum albumin. 
(Park et al 2005) Microneedles encapsulating small molecules and proteins 
within PLGA have also been shown to deliver their payload over extended 
periods of times. As a result, controlled drug delivery is achievable with the 
microneedles for periods of hours to months depending on the formulation and 
encapsulation methods (Park et al 2006). It has also been shown that 
microneedles made of carboxymethylcellulose (CMC) could be designed to insert 
and degrade in the skin to deliver a drug. Figure 2.4.4 shows a polymer 
microneedle array made of CMC. A micromolding and encapsulating method was 
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developed to deliver a model protein, lysozyme into pig cadevar skin. The 
enzymatic activity of lysozyme after 2 months within the microneedle array was 
96 % of the initial activity indicating the processing conditions and microneedle 
formulation were benign to the enzyme.  By encapsulating drug into the backing 
layer in addition to the microneedle shaft, the microneedles and patch could be 
used to provide sustained drug delivery (Lee et al 2008). Although these 
microneedles have not been inserted or tested in eye tissues, they could 
conceivably be inserted in a similar fashion for ocular drug delivery. 
 
 
Figure 2.4.4 An array of carboxymethylcellulose (CMC) microneedles of 600 μm 
in length and a base of 300 μm. Scale bar: 500 μm. Adapted from Lee et al 2008. 
 
2.4.5 Poke and Flow  
The poke-and-flow approach to using a microneedle is analogous to the 
hypodermic needle. A hollow microneedle is inserted within a tissue and a liquid 
formulation can be injected through the hollow cannula in the microneedle for 
delivery within a tissue at depths of less than a millimeter. Hollow microneedles 
provide unique capabilities such as being able to inject formulations and to 
immediately spread the injected formulation within tissues. This is in contrast to 
other microneedle designs and approaches which deposit the drug only locally to 
the insertion site. This is advantageous from two aspects.  The most important 
aspect for the eye is the ability to deliver a drug to a site that is not directly 
accessible. This is an important element in suprachoroidal delivery because the 
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microneedle is inserted at an accessible portion of the eye and the formulation is 
spread within the suprachoroidal space to an inaccessible region further back in 
the eye. The other important aspect is that a hollow microneedle allows more of a 
drug to be delivered in a single injection compared to other microneedle 
strategies. This is because a hollow microneedle simply serves as a conduit for 
delivery whereas in other scenarios the surface area or volume of the 
microneedle is limiting the amount of drug that can be delivered from a single 
insertion. 
Fabrication of hollow microneedles can be challenging because an 
internal bore needs to be created within the structure and this may compromise 
the integrity of the microneedle. Hollow metal microneedles have been made 
from micromolding and etching techniques. These techniques can be used to 
make hollow silicon, nickel, and gold microneedles (Gardeniers et al 2003, 
McAllister et al 2003). Glass microneedles fabricated using a micropipette pulling 
techniques have been shown to effectively insert and deliver into skin. Figure 
2.4.5 shows a hollow microneedle made from this process. Martanto et al (2006) 
showed that in addition to microneedle insertion and infusion parameters the 
tissue itself can be a limiting factor in how much volume can be delivered. Ex-
vivo experiments showed that partial retraction of the hollow microneedle aided 
in infusing fluid into the skin and reducing the compaction of skin that occurs at 
the site of insertion (Martanto et al 2006). Hollow microneedles have also been 
shown to deliver insulin into human skin in vivo. Experiments on humans using 
hollow microneedles showed that delivering a bolus injection of insulin into the 
dermis were effective at reducing blood glucose levels with kinetics that were 




Figure 2.4.5 (a) Front and (b) side view of a single hollow glass microneedle. 
The microneedle has a beveled tip and an approximately elliptical orifice. Scale 
bar: 250 µm. Adapted from Jiang et al 2009. 
 
Hollow microneedles may be able to spread a fluid within the sclera 
collagen matrix and accomplish intrascleral delivery of fluids. The first reported 
study to show that a hollow microneedle was capable of intrascleral injection 
demonstrated delivery of a sulforhodamine solution within the sclera of human 
eyes in vitro. Bare sclera was excised from human cadaver eyes and a hollow 
glass microneedle was inserted into the sclera and infused with a solution. The 
delivery and spread of sulforhodamine solution within the sclera showed that a 
hollow microneedle can inject a solution intrasclerally and target the sclera tissue 
(Jiang et al 2009). 
In addition to injecting a solution intrasclerally, injection of nano or 
microparticles has also been demonstrated. Nanoparticles of 280 nm in diameter 
with up to 10 wt. % suspension were injected into the sclera with an applied 
pressure of 15 psi. Injections were performed in different region of the sclera 
tissue to determine if a hollow microneedle was capable of injecting 
nanoparticles into all regions. Hollow microneedles were capable of injecting into 
all regions of the sclera implying that a hollow microneedle can inject 
intrascelrally to any site that can be accessible on the eye. However, the spread 
in the posterior region of the sclera did appear to be over a larger area than the 
other regions. This showed that nanoparticles could be injected intrasclerally 
similarly to the way fluids were injected into the sclera (Jiang et al 2009).    
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However, administration of microparticle suspensions intrasclerally was 
not as straightforward. Suspensions of microparticles did not flow through the 
sclera tissue. This is in large part attributed to the spacing of the collagen fibers 
rather than a limitation on the microneedle capability. The collagen fiber spacing 
is on the order of several hundred nanometers, and as a result microparticles 
may not easily flow within this medium (Edwards and Prausnitz 1998). To test 
this hypothesis two approaches were employed to aid the movement of particles 
in the dense collagen matrix. One was the use of collagenase to break up the 
collagen structure and provide larger pathways for microparticles to flow through 
the sclera. The sclera tissue was either soaked in collagenase prior to injection or 
the collagenase was co-injected with the microparticle suspension.  Both of these 
steps allowed infusion of the microparticle suspension demonstrating that 
disruption of the collagen structure allowed microparticle infusion within the 
sclera. The second approach involved coinjecting hylauronidase, a dispersive 
agent known to help injectable formulations flow through densely packed tissues 
such as the skin. Microparticles were also successfully administered using this 
approach. As a result, incorporation of hylauronidase into a suspension may be a 
feasible way to deliver controlled release microparticle formulations within the 
sclera for drug delivery to the back of the eye (Jiang et al 2009). 
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CHAPTER 3  
MATERIALS AND METHODS 
 
3.1 Feasibility of Suprachoroidal Delivery Using a Hollow Microneedle 
3.1.1 Materials  
 Whole  rabbit eyes (Pel-Freez Biologicals, Rogers, AR), pig eyes (Sioux-
Preme Packing, Sioux Center, IA) and human eyes (Georgia Eye Bank, Atlanta, 
GA), all with the optic nerve attached, were shipped on ice and stored wet at 4 °C 
for up to 3 days. Prior to use, eyes were allowed to come to room temperature 
and any fat and conjunctiva were removed to expose the sclera.  
Hollow microneedles were fabricated from borosilicate micropipette tubes 
(Sutter Instrument, Novato, CA), as described previously (Jiang et al 2009).  A 
custom, pen-like device with a threaded cap was fabricated to position the 
microneedle and allow precise adjustment of its length. The device was made of 
aluminum and contained a threaded internal backside. An olive shaped gasket fit 
into this backside and was attached to a micropipette holder (MMP-KIT, World 
Precision Instruments, Sarasota, FL) with tubing that was connected to a carbon 
dioxide gas cylinder for application of infusion pressure. The olive gasket 
provided a seal between the hollow glass microneedle and the holder. The holder 
was attached to a micromanipulator (KITE, World Precision Instruments) which 
was used to control insertion of the microneedle into the sclera. Figure 3.1.1 
shows a hollow microneedle held in the device compared to the tip of a 30 gauge 
hypodermic needle.   
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Figure 3.1.1 Experimental approach to microneedle infusion into the 
suprachoroidal space. (a) Comparison of a hollow microneedle mounted in an 
insertion device (above) and the tip of a 30 gauge hypodermic needle (below). 
Scale bar: 1mm. (b) Schematic diagram of the experimental set up used to study 
suprachoroidal injection. The eye was placed on a custom-made mold with a 
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channel through which suction was applied to hold the eye in place. A cannula 
inserted through the optic nerve of the eye allowed application of intraocular 
pressure. The microneedle was inserted into the sclera using the custom-made 
insertion device. Image of the eye was adapted from National Eye Institute, 
National Institutes of Health with permission. 
 
Carboxylate-modified FluoSpheres (Invitrogen, Carlsbad, CA) were 
injected as 2 wt % solids suspension of 20 nm, 100 nm, 500 nm, and 1000 nm 
diameter particles. Tween 80 (Sigma-Aldrich, St. Louis, MO) at a final 
concentration of 0.5 wt %, was added to the suspension and sonicated prior to 
use. The fluospeheres were made of polystyrene and are not biodegradable. 
Sulforhodamine B (Sigma-Aldrich) was dissolved in Hanks’ balanced salt solution 
(Mediatech, Manassas, VA) to make a sulforhodmine solution of 10-4 M. Barium 
sulfate particles (Fisher Scientific, Waltham, MA) measuring 1 µm in diameter 
were suspended in balanced salt solution (BSS Plus, Alcon, Fort Worth, TX) to 
form a 1.5 wt % suspension.  
 
3.1.2 Experimental Procedure  
A custom acrylic mold, shaped to fit a whole eye, was built to hold the eye 
steady and used for all experiments (Figure 3.1.1b). A catheter was inserted 
through the optic nerve into the vitreous and connected to a bottle of BSS Plus 
raised to a height to generate internal eye pressure of 18 mm Hg unless 
otherwise specified. Suction was applied to a channel within the mold to hold the 
external surface of the eye steady during microneedle insertion and 
manipulation. Each microneedle was pre-filled using flexible quartz tubing (World 
Precision Instruments) with a desired volume of the material to be injected. The 
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microneedle was placed in the device holder at a set microneedle length, 
attached to the micromanipulator and connected to the constant pressure source. 
Microneedles were then inserted perpendicular to the sclera tissue 5-7 mm 
posterior from the limbus. A set pressure was applied to induce infusion. Thirty 
seconds were allowed to see if infusion of the solution began. If infusion 
occurred, the pressure was stopped immediately upon injection of the specified 
volume. If visual observation of the injected material showed localization in the 
suprachoroidal space, the injection was considered a success. If infusion had not 
begun within that timeframe, then the applied pressure was stopped and the 
needle was retracted. This was considered an unsuccessful delivery. 
Eyes to be imaged using microscopy were detached from the set-up within 
minutes after delivery was completed. The eyes were placed in acetone or 
isopentane which was kept on dry ice or liquid nitrogen causing the eye to freeze 
completely within minutes after placement. The frozen eye was removed from the 
liquid and portions of the eye were hand cut using a razor blade for imaging of 
injected material. Imaging was performed using a stereo microscope using 
brightfield and fluorescence optics (model SZX12, Olympus America, Center 
Valley, PA). The portions containing the sclera, choroid and retina were placed in 
Optimal Cutting Temperature media (Sakura Finetek, Torrance, CA) and frozen 
under dry ice or liquid nitrogen. These samples were cryosectioned 10-30 µm 
thick (Microm Cryo-Star HM 560MV, Walldorf, Germany) and imaged by 
brightfield and fluorescence microscopy (Nikon E600, Melville, NY) to determine 
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the location of injected material in the eye. Images were collaged as necessary 
using Adobe Photoshop software (Adobe Systems, San Jose, CA). 
Pig eyes used for microcomputed tomography imaging were not frozen 
after injection. Instead pig eyes were injected with the barium sulfate suspension 
and stabilized in a 30 mm diameter sample tube and scanned in air using a 
Scanco µCT40 desktop conebeam system (Scanco Medical AG, Brüttisellen, 
Switzerland) at 30 µm isotropic voxel size, E = 55 kVp, I = 145 µA, and 
integration time = 200 ms.  Through a convolution backprojection algorithm 
based on techniques from Feldkamp et. al. (Feldkamp et al 1984), raw data were 
automatically reconstructed to generate 2D grayscale tomograms. Global 
segmentation values (Gauss sigma, Gauss support, and threshold) were chosen 
for the contrast-enhanced region as well as general eye tissue. Grayscale 
tomograms were stacked, and 3D binarized images were produced by applying 
the optimal segmentation values (one image for the entire eye and another for 
the region injected with contrast agent). These images were overlayed using 
Scanco image processing language to demonstrate the relative 3D position of 
the contrast-enhanced region within the entire eye.  
 
3.2 Spread of Injections in the Suprachoroidal Space 
3.2.1 Hollow Glass Microneedle Device  
 Hollow microneedles were fabricated from borosilicate micropipette tubes 
(Sutter Instrument, Novato, CA), as described previously (Jiang et al 2009).  A 
simple device was designed to hold a hollow glass microneedle that could be 
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inserted into the sclera of a rabbit eye in vivo and used to inject a fluid into the 
suprachoroidal space. Figure 3.2.1 shows the whole device. The main housing of 
the custom device (1-3) contains a shaft through which a hollow glass 
microneedle can be inserted. The tip of the microneedle extends from the tip of 
the cap on the housing (2). The cap can be rotated so as to allow the desired 
amount of the glass microneedle to protrude from the device. The microneedle 
length is adjusted using this rotatable cap. The back end of the device is 
connected to a metal luer adapter (S4J Mfg, Cape Coral FL) containing an olive 
shaped gasket (4).  One end of the adapter is screwed onto to the device which 
tightens onto the glass microneedle and holds it in place. The other end of the 
luer adapter could be attached to any male luer tubing (5) or syringe (6). For 
these experiments a 7 inch extension tubing (Wolf Medical Supply, Sunrise FL) 
was used. The opposing end of the tubing is directly attached to a glass syringe 




Figure 3.2.1 A custom hollow microneedle device for injection of fluids in vivo in 
to the rabbit suprachoroidal space. The main housing of the custom device (1-3) 
contains a shaft through which a hollow glass microneedle can be inserted 
through. The tip of the microneedle extends from the tip of the cap on the 
housing (2). The cap can be rotated so as to allow the desired amount of the 
glass microneedle to protrude from the device. The microneedle length is 
adjusted using this rotatable cap. The back end of the device is connected to a 
metal luer adapter containing an olive shaped gasket (4).  One end of the 
adapter is screwed onto to the device which tightens onto the glass microneedle 
and holds it in place. The other end of the luer adapter is attached to extension 
tubing which is attached to a glass syringe. Scale bar: 1 cm.  
 
3.2.2 Injection of India Ink 
 New Zealand white rabbits were used for all experiments in this study. All 
experiments were approved by the Emory Institutional Animal Care and Use 
Committee (IACUC) and complied with the ARVO statement for animal use. 
Animals were anesthetized with an intramuscular injection of ketamine (Hospira 
Inc, Lake Forest IL) and xylazine (Lloyd Inc, Shenandoah IA) prior to injection of 
a formulation within the eye. Black colored India ink (Speedball, Statesville NC) 
was diluted in deionized water to make a 1:20 India ink: water suspension.    
 While the rabbit was anesthetized, the eye was proctosed by pulling the 
eyelids back to expose the sclera of the rabbit eye. The cap on the microneedle 
device was set to the desired microneedle length (7-800 µm). The microneedle 
was inserted using the device into the superior temporal region of the eye 
approximately 3-4 mm posterior to the limbus.  The desired amount of India ink 
was injected using the syringe. Approximately 20-30 seconds were allowed after 
injection to ensure complete injection of fluid and then the microneedle and 
device were removed from the eye. Any observation of leakage was noted and 
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the lids were pushed to normal position. Within minutes after injection the animal 
was euthanized with an overdose of pentobarbital and the eyes were enucleated.  
 
3.2.3 Snap Freezing of the Eye 
 One way the delivery of India ink into the suprachoroidal space was 
confirmed was using the snap freeze method. Enucleated eyes were sutured at 
the limbus onto a plastic plate that contained an opening for the cornea along 
with tiny holes for the sutures around the cornea hole. The eye and plastic plate 
were dipped in isopentane which was kept under dry ice or liquid nitrogen. Within 
a few minutes eyes were frozen and removed from the isopentane bath. Using a 
surgical blade a cut was made across the sclera and into the vitreous, without 
penetrating into the vitreous, along the entire equator of the eye. This allowed the 
back half of the eye to be removed as a cup leaving behind the vitreous and 
other half of the eye on the plastic plate. The inside of the cup exposed the black 
India ink and the vitreous could then be examined for traces of India ink.  During 
the whole process the eye was still frozen preventing any movement of the India 
ink or tissues.  
  
3.2.4 Histological Analysis 
For histological analysis of India ink injections the whole eye was fixed in 
2.5% glutaraldehyde in 0.1 M cacodylate buffer overnight. A sample of the eye 
was cut from the injection site of the eye for analysis. The sample was rinsed, 
postfixed in 1% osmium tetroxide, en bloc stained with uranyl acetate and then 
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dehydrated in a graded series of ethanol baths. After a final wash in 100 % 
ethanol it was given 2 changes of propylene oxide and placed in a 1:1 mixture of 
propylene oxide and LX-112 resin (Ladd Research Industries, VT) overnight. The 
next day, tissue was transferred into pure resin, embedded in flat molds and 
placed in a 50-60 °C oven to polymerize.  1.5 um thick sections were cut and 
stained with 1% toluidine blue on a Leica ultracut UCT. Tissue blocks were 
trimmed down to the areas of interest and 70-80 nm thin sections were cut and 
placed on grids.  Sections were stained with 2% uranyl acetate for 30 minutes 
followed by lead citrate.  
 
3.2.5 Quantification of the Spread of India Ink 
Enucleated eyes were placed in glycerol for 6-8 minutes causing the sclera to 
become transparent. The eye was removed when the India ink could clearly be 
seen. Images of the eye were taken using a Sony DSCH-50 digital macro 
camera (Sony Corporation, Tokyo Japan). Now that the India ink could clearly be 
seen measurements were also taken of the spread. Using the images and 
measurements a digital map of the spread was made for each injection. On this 
digital map the location of the limbus, the injection site, and the optic nerve were 
designated. Figure 3.2.2 shows a graphical representation of this process. The 
digital images were then used to quantify the area of the spread and distances 
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using Photoshop (Adobe Systems, San Jose CA) computer imaging software.   
 
Figure 3.2.2 India ink surface area coverage quantification process. (a) Eyes 
were enucleated after injection of India ink. (b) Enucleated eyes were placed in 
glycerol for 6-8 minutes causing the sclera to become transparent. (c) The eye 
was removed when the India ink could clearly be seen. Images of the eye were 
taken using digital camera. The India ink could clearly be seen and 
measurements were taken of the spread. (d) Using the images and 
measurements a digital map of the spread was made for each injection. On this 
digital map the location of the limbus, the injection site (asterisk), and the optic 
nerve were designated. 
 
3.2.6 Hollow Metal Microneedle Device 
A hollow metal microneedle device was created for injection of latex into 
the suprachoroidal space of human eyes. The microneedles were made form 33 
gauge stainless steel hollow hypodermic needles (TSK Laboratories, Tochigi, 
Japan). The hypodermic needles were fixed onto a custom plastic holder that 
kept the cannula flat on the surface and the luer adapater flush against the 
plastic end. The cannula was cut using an infrared laser (Resonetics Maestro, 
Nashua, NH) at a desired angle and length from the base of the luer adapter. 
The microneedle was electoropolished using an E399 electropolisher (ESMA, 
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South Holland IL) and cleaned with deionized water. Microneedles were sterilized 
as necessary using an AN74j anaprolene sterilizer (Anderson Products Inc, Haw 
River NC). An image of a finished microneedle is shown in Figure 3.2.4 in 
comparison to a 30 gauge hypodermic needle. The luer of the microneedle can 




Figure 3.2.3 Comparison of hollow metal microneedle to a 30 gauge 
hypodermic needle. The hollow metal microneedle is on the left attached to a 
standard luer adapter (in white) which could be easily attached to any syringe.  
The total length of the microneedle is less than a millimeter which is similar to 
just the orifice opening of the 30 gauge hypodermic needle.  
 
3.2.7 Injections of Latex into Human Eyes 
 Whole human eyes were obtained from Lions Eye Institute for Transplant 
Research (Tampa FL). A custom acrylic mold, shaped to fit a whole human eye, 
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was built to hold the eye steady and used for all experiments. A catheter was 
inserted through the optic nerve into the vitreous and connected to a column of 
BSS Plus raised to a specific height to generate internal eye pressure of 15 mm 
Hg. Red latex (Carolina Biological Supply Company, Burlington NC) was diluted 
to make a 1:4 Latex: BSS mixture. The mixture was sonicated for 3-5 minutes 
and made fresh before each injection. The desired volume of the mixture was 
loaded into a syringe and the microneedle was then attached to the syringe. The 
microneedle was inserted 8 mm posterior the limbus, across the sclera, and the 
latex mixture was injected. Thirty seconds were allowed after injection, and the 
microneedle was removed. The eye was then immediately snap frozen.   
   The optic nerve of the eye was attached to a suture or string and was 
dipped in isopentane which was kept under a dry ice bath. The eye was 
completely frozen within approximately 5 minutes. Once the whole eye was 
frozen the globe was dissected using a blade into “petals” starting from the optic 
nerve. The cuts were made up to the cornea leaving the cornea intact. The petals 
were opened up from the optic nerve. The petals contained the tissues of the 
globe (sclera, choroid and retina) and exposed the vitreous inside as a frozen 
white ball. The vitreous was removed carefully leaving the globe tissues and 
anterior segments of the eye. The petals were laid flat with the cornea in the 
center and the choroid and retina were slowly pulled away. This left behind latex 
(pink in color) on the sclera that could be easily distinguished from the white 
sclera with the transparent cornea in the center of the petals.  Figure 3.2.4 shows 




Figure 3.2.4 Latex surface area quantification procedure. (a) First the whole eye 
was frozen. The globe was dissected using a blade into “petals” starting from the 
optic nerve. (b) The cuts were made up to the cornea leaving the cornea intact. 
The petals were opened up from the optic nerve. The petals contained the 
tissues of the globe (sclera, choroid and retina) and exposed the vitreous (1) 
inside as a frozen white ball. (c) The vitreous was removed carefully leaving the 
globe tissues and anterior segments of the eye. The petals were laid flat with the 
cornea in the center and the choroid and retina (2) were slowly pulled away.  
Image (c) shows petals with choroid and retina still attached (2) and choroid and 
retina removed (3). (d) Once all the petals were removed the latex (4) on the 
sclera that could be easily distinguished from the white sclera with the 
transparent cornea (5) in the center of the petals.  
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 Images of the latex spread, such as 3.2.4d were taken with a scale. The 
surface area could then be quantified from the images by determining the area 
that the pink latex covered. The total area could be determined by calculating the 
area of the white colored sclera plus the pink latex covered area. This was 
performed by scaling each image and using imaging software, Photoshop 
(Adobe Systems, San Jose CA). With these images additional measurements 
such as distances were also made.  
 
3.3 In Vivo Ocular Distribution of Molecules and Particles 
3.3.1 Materials 
Hollow microneedles were fabricated from borosilicate micropipette tubes 
(Sutter Instrument, Novato, CA), as described previously (Jiang et al 2009).  The 
custom device for hollow glass microneedles described in section 3.2.1 was used 
for injections of all molecules and nanoparticles within the suprachoroidal space. 
The hollow metal microneedle described in section 3.2.6 was used for injections 
of all microparticles within the suprachoroidal space.   Microneedles were 
sterilized using an AN74j anaprolene sterilizer (Anderson Products Inc, Haw 
River NC) as necessary.  
 Several formulations were prepared for injection into the eye. Sodium 
fluorescein (Sigma-Aldrich, St. Louis, MO) and dextrans of 40 kDa and 250 kDa 
tagged with fluorescein isothiocyanate, FITC, (Sigma-Aldrich, St. Louis, MO) 
were dissolved in Hanks Balanced Salt Solution (Mediatech, Manassas, VA). 
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Avastin was tagged with a fluorophore, Alexa-Fluor 488, and was dissolved in 
Hanks Balanced Salt Solution (HBSS).  The Avastin was provided courtesy of 
Dr. Uday Kompella’s lab at the University of Colorado. Particles of 20 nm, 500 
nm, 1 µm, and 10 µm (FluoSpheres) were purchased from Invitrogen (Carlsbad, 
CA). All particle suspensions were in an aqueous media at 2 wt. % solids except 
for the 10 µm suspension which contained approximately 0.2 wt. % solids.    
New Zealand white rabbits were used for all experiments in this study. All 
experiments were approved by the Emory Institutional Animal Care and Use 
Committee (IACUC) and complied with the ARVO statement for animal use. 
Animals were anesthetized with an intramuscular injection of ketamine (Hospira 
Inc, Lake Forest IL) and xylazine (LLoyd Inc, Shenandoah IA) prior to injection of 
a formulation within the eye. Animals were sacrificed with an injection of 
pentobarbital through the ear vein as necessary for histology. 
 
3.3.2 Injection Procedure 
The custom metal device was used to insert a hollow glass microneedle 
into the rabbit eye across the conjunctiva and into the sclera several millimeters 
past the limbus. Hollow metal microneedles were inserted directly into the sclera 
in a similar fashion. The eye was exposed by pushing back the eyelids and 
exposing the eyeball from the socket. The injection site was in the superior 
temporal quadrant of the eye. Once the microneedle was inserted, the 
appropriate volume was injected by hand using a 1 mL syringe. After complete 
injection, approximately 30 seconds were allowed before removing the 
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microneedle and device from the surface of the eye. Hollow metal microneedles 
were used to inject 1 and 10 µm particles; all other materials were injected with a 
hollow glass microneedle.  Intravitreal injections were performed using a 30 
gauge needle and the needle was inserted transclerally and the formulation was 
injected near the mid-vitreous.  The opposing eye was used as a control eye and 
nothing was injected into the eye.  
 
3.3.3 Fluorescence Measurements 
Measurement of fluorescence intensity within the rabbit eye was 
performed using an ocular fluorophotometer (Ocumetrics, Mountain View, CA). 
The system is tuned for measuring fluorescence measurements that are within 
the excitation and emission wavelengths of sodium fluorescein. No anesthesia 
was necessary for scanning and animals were awake for the entire process. The 
pupil was dilated using drops of a 2.5% solution of phenylephrine hydrochloride 
(Baush & Lomb, Tampa FL). The eye was aligned to allow light to pass through 
the anterior portion of the eye through the pupil and vitreous to the retina, 
choroid, and sclera in the back of the eye. A one dimensional scan of the 
fluorescence intensity from the front to the back of the eye was obtained from 
each scan. A baseline scan, a scan of the eye with no injection, was obtained for 
each eye prior to injection. Baseline scans provided details on location of tissues 
and background fluorescence within the eye. Figure 3.3.1 shows the results of a 
baseline fluorescence scan of the eye.  
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Figure 3.3.1 Representative baseline fluorescence scan of the rabbit eye in vivo.  
(a) The baseline scan is performed through the visual axis, dotted box area. (b) 
The scan of that region gives fluorescence measurements along this axis and 
assigns a relative position (x-axis). The fluorescence reading is plotted on the y-
axis. The peaks provide an indication as to the position of key regions of the eye 
such as the retina, lens and cornea. The image of the eye is roughly scaled to 
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match the position axis of the scan for reference. Image of the eye was adapted 
from National Eye Institute, National Institutes of Health with permission. 
 
3.3.4 Imaging Delivery into the Suprachoroidal Space 
In order to image the fundus of the rabbit eye in-vivo, a Genesis-D 
handheld digital retina camera (Kowa Optimed Inc, Torrance CA) was used. 
Tropicamide (Baush & Lomb, Tampa FL) was applied topically to dilate the pupil 
and the animal was imaged while under anesthesia. A 90 diopter lens was used 
to allow for a wider field of view. Fundus images of the injected eye were taken 
through the pupil to evaluate any abnormalities compared to the uninjected eye. 
Using the fluorescence mode, images of the fundus were taken to confirm the 
presence of the particles in the eye.    
Eyes to be imaged using microscopy were enucleated from the animal 
after sacrafice. The eyes were fixed in 2.5% glutaraldehyde in 0.1 M cacodylate 
buffer overnight. A tissue section of the eye near the injection site was removed 
for cryosectioning. The portions containing the sclera, choroid and retina were 
placed in Optimal Cutting Temperature media (Sakura Finetek, Torrance CA) 
and frozen under dry ice or liquid nitrogen. These samples were cryosectioned 
10-30 µm thick (Microm Cryo-Star HM 560MV, Walldorf Germany) and imaged 
by brightfield and fluorescence microscopy (Nikon E600, Melville NY) to 
determine the location of injected material in the eye. Images were overlayed as 
necessary using Adobe Photoshop software (Adobe Systems, San Jose CA). 
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CHAPTER 4  
RESULTS 
 
4.1 Feasibility of Suprachoroidal Delivery Using a Hollow Microneedle 
4.1.1 Introduction  
In this study, we investigate the suprachoroidal space as a route to target 
delivery of drugs to the back of the eye.  The suprachoroidal space is a potential 
space between the sclera and choroid that goes circumferentially around the eye 
(Krohn and Bertelsen 1998, Einmahl et al 2002).  Previous studies employing 
surgical procedures to introduce catheters into this space have shown that drugs 
delivered into the suprachoroidal space can be targeted towards the choroid and 
retina because the suprachoroidal space is in direct contact with the choroid 
(Einmahl et al 2002, Gilger et al 2006, Olsen et al 2006, Kim et al 2007). 
Introduction of controlled release formulations into the suprachoroidal space 
could further enable long-term therapy. Access to the suprachoroidal space, 
however, is difficult and the methods that have previously been studied are 
invasive and too complex to be performed as a simple office procedure (Einmahl 
et al 2002, Gilger et al 2006, Olsen et al 2006, Kim et al 2007).  
We hypothesize that hollow microneedles can provide a minimally 
invasive method to inject nanoparticles and microparticles into the suprachoroidal 
space for drug delivery to the back of the eye. Hollow microneedles are needles 
of micron dimensions that can infuse fluid into tissue with excellent spatial 
targeting. Fabrication and characterization of hollow microneedles has been 
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extensively studied for drug delivery to the skin (Brazzle et al 1999, Zahn et al 
2000, Gardeniers et al 2003, McAllister et al 2003, Davis et al 2005), including 
recent human studies administering insulin (Gupta et al 2009) and influenza 
vaccine (Van Damme et al 2009). Another recent study showed that hollow 
microneedles can pierce hundreds of microns into the ocular tunic and inject 
small molecules and particles into the sclera and corneal stroma (Jiang et al 
2009).  
We seek to determine if microneedles can pierce to the base of the sclera 
and target the suprachoroidal space. Suprachoroidal delivery using microneedles 
has the promise to be simple, minimally invasive, targeted, and able to achieve 
sustained release by injecting nanoparticles and microparticles encapsulating 
drug for slow release.     
More specifically, this study determines whether hollow microneedles can 
deliver small molecules and particles to the suprachoroidal space of pig, rabbit 
and human cadaver eyes. We further measure the effect of microneedle length, 
infusion pressure, and intraocular pressure on the delivery of particles ranging 
from 20 -1000 nm in diameter in pig eyes. Finally, we examine the role that 
particle size plays and the influence of ocular anatomical barriers on delivery to 
the suprachoroidal space. With this work, we show for the first time that 
microneedles are capable of delivering fluid and particles into the suprachoroidal 
space in a minimally invasive manner to deliver drugs to the back of the eye. 
 
4.1.2 Imaging Delivery in to the Suprachoroidal Space  
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Because microneedles have not been used before to inject into the 
suprachoroidal space, we first wanted to determine if a liquid formulation could 
be delivered, what volume could be delivered, and over how large an area it 
would spread. We used red-fluorescent sulforhodamine B as a model compound 
and injected it into pig eyes ex vivo using a single hollow microneedle inserted 
just to the base of the sclera in order to target the suprachoroidal space. Using 
this approach, we found that it is possible to inject a liquid formulation into the 
suprachoroidal space and spread it circumferentially around the eye from a 
single microneedle injection, as discussed immediately below.  
Figure 4.1.1a shows a saggital cross section of an untreated pig eye. The 
layers of the eye can be distinguished and the white colored sclera is in direct 
contact with the dark colored layer that represents the choroid and retinal 
pigment epithelium. Figure 4.1.1b shows a sagittal cross section of a pig eye 
frozen after injection of 35 µL of sulforhodamine. The pink sulforhodamine 
solution can be seen selectively delivered just below the sclera and above the 
choroid. This region represents the suprachoroidal space and confirms that the 
solution was injected and spread within the suprachoroidal space from the initial 
injection site. Examining the injection form the inside further confirms the location 
of the sulforhodamine.  
Figure 4.1.2a shows a section of the pig globe with the vitreous removed 
and parts of the choroid and retina still attached to the sclera. Where the retina 
and choroid are missing the sulforhodamine solution is visible. When the choroid 
and retina are completely removed, Figure 4.1.2b, the sulforhodamine can clearly 
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be seen underneath where these tissues were. We were able to inject volumes 
up to 35 µL without leakage, but larger volumes leaked out from openings on the 
surface of the eye where vortex veins would be attached in vivo. However, 
subsequent experiments in pigs and rabbits in vivo have demonstrated 




Figure 4.1.1 Imaging of fluid infusion into the suprachoroidal space. Brightfield 
microscopic images of a cross section of a frozen eye (a) showing normal ocular 
tissue (b) showing the delivery of sulforhodamine B (pink) between the sclera 




Figure 4.1.2 Imaging of sulforhodamine B (pink) infusion into the suprachoroidal 
space. Brightfield view of a frozen eye from the vitreous side (a) showing the 
sample with choroid and retina still attached in some locations and (b) with 
choroid and retina completely removed. 
 
We next wanted to determine if microneedles can also deliver particles 
into the suprachoroidal space, which is of interest for sustained-release drug 
delivery scenarios. We therefore injected particles with diameters of 500 nm or 
1000 nm into the suprachoroidal space of rabbit, pig and human eyes ex vivo 
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and imaged their distribution to confirm their localization just below the sclera. 
Cryosections of the rabbit eye were taken in the axial plane and images were 
collaged to form a panoramic view, as shown in Figure 4.1.3b. The images show 
the spread of the fluorescent (red/orange) particles along the equator of the eye 
in a thin sheath just below the sclera. In this experiment, a volume of 15 µL was 
injected and in this particular cross-section taken in the plane of the insertion site, 
the injection has spread approximately 20 mm, which corresponds to about 36% 
of the total circumference of the eye.  
As shown in Figure 4.1.3c-d, cryosections of pig and human eyes were 
taken in the saggittal directions so that the images show the anterior of the eye to 
the right and the posterior of the eye to the left.  These images show the ability of 
microinjected particles to spread in the suprachoroidal space both in the anterior 
and posterior direction of the eye from the injection site. In these experiments, a 
single microneedle delivered 30 µL of a 2 wt % particle suspension into the 
suprachoroidal space of both species.  Leakage was observed at the vortex vein 
openings away from the injection site similar to what was observed with 




Figure 4.1.3 Imaging of particle infusion into the suprachoroidal space. Image of 
a cryosection of a pig eye with no infusin into the suprachoroidal space. (a) The 
layers of the eye are (1) sclera, (2) choroid, and (3) retina. Collaged fluorescence 
microscopy images of tissue cryosections show the delivery of (b) 500 nm 
particles into a rabbit eye, (c) 500 nm particles into a pig eye, and (d) 1000 nm 
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particles into a human eye, all ex vivo. Each image also displays an inset with a 
magnified view of the microneedle insertion site. These images show targeted 
delivery of particles into the suprachoroidal space and indicate that the 
microneedle did not penetrate into the choroid or retina. Scale bar: 500 µm. 
 
 
 The insets in these images show magnified views of the microneedle 
insertion site. In each case, the insertion site within the sclera is filled with 
particles. In the case of the pig and human, the retina is still attached and visible, 
and it is clear that the microneedle has not penetrated to the retina. The rabbit 
retina separated during the cryosectioning procedure and is not visible. These 
results confirmed that a microneedle was able to target the suprachoroidal space 
of rabbit, pig, and human eyes to deliver particles up to 1000 nm in diameter, 
which was the largest particle size used in this study. These particles spread 
from the injection site circumferentially in all directions within the suprachoroidal 
space.  
To image the circumferential spread and localization of injected material in 
the suprachoroidal space in three dimensions using a noninvasive method, we 
utilized microcomputed tomography (µCT). After injecting 35 µL of 1 µm diameter 
barium sulfate contrast agent particles into the suprachoroidal space of a pig eye, 
cross sectional images showed the particles distributed as a thin white strip that 
circled just below the outer edge of the eye, i.e., just below the sclera (Figure 
4.1.4a). This profile is characteristic of suprachoroidal delivery and similar to the 
results from fluorescence imaging. The three-dimensional reconstruction of these 
cross-sectional images shows the spread of the particles in the posterior 
segment of the eye (Figure 4.1.4b).  The particle spread is approximately 5 mm 
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in radius, although asymmetrically distributed around the injection site, and 
covers an approximate area of 70 mm2 which represents 7 % of the surface area 
of the back of the eye. This further confirms the ability of microneedles to spread 
particles over a significant portion of the posterior segment of the eye by 




Figure 4.1.4 Microcomputed tomography images of suprachoroidal delivery of 
barium sulfate particles. (a) Two-dimensional axial cross section of a pig eye 
imaged after injection of 1 µm barium sulfate particles. The arrow points to the 
thin white strip of particles in the suprachoroidal space. (b) Two-dimensional 
cross sections were reconstructed to form a three-dimensional map showing the 
distribution of particles, which have spread circumferentially in all directions 
around the microneedle insertion site (arrow) in the suprachoroidal space. Scale 
bar: 5 mm. 
 
 
4.1.3 Effect of Operating Parameters on Particle Delivery in to the 
Suprachoroidal Space of Pig Eyes 
 
We hypothesize that injection into the suprachoroidal space is facilitated 
by the use of longer microneedles, greater infusion pressure and smaller particle 
size. To test this hypothesis, we injected particles of 20, 100, 500, and 1000 nm 
diameter into pig eyes ex vivo using a range of different microneedle lengths and 
infusion pressures to determine the success rate of suprachoroidal delivery. Our 
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observation was that an attempted injection is either fully successful, as defined 
as complete injection of the 25 µL particle suspension into the suprachoroidal 
space, or fully unsuccessful, as defined as an inability to inject at all. Partial 
injections were not observed. The success rates after five injection attempts at 
each condition are shown in Figure 4.1.5.  
In each of the graphs, the success rate increased with greater infusion 
pressure and with greater microneedle length (ANOVA, p<0.05). For the smallest 
particles (20 nm), 100% successful injections were achieved using a pressure of 
250 kPa at all microneedle lengths. For 100 nm particles, the effects of pressure 
similarly plateaued at 250 kPa and 100% success was achieved at all but the 
shortest microneedle length (700 µm). For the larger particles (500 and 1000 
nm), the effects of pressure generally plateaued at 300 kPa and success rate 





Figure 4.1.5 The effect of infusion pressure and microneedle length on the 
success rate of suprachoroidal delivery for (a) 20 nm, (b) 100 nm, (c) 500 nm and 
(d) 1000 nm particles into pig eyes. A total of five infusions were attempted at 
each condition studied. Increasing microneedle length and increasing infusion 




We interpret these data in the following way. Short microneedles lengths 
inject within the sclera, such that particles must be forced through a portion of the 
sclera to reach the suprachoroidal space. Smaller particles (20 and 100 nm) can 
do this more easily, because the spacing of collagen fiber bundles in the sclera is 
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on the order of 300 nm (Edwards and Prausnitz 1998, Meek and Fullwood 2001). 
The ground substance between the collagen fibers, which has a much smaller 
pore size (Edwards and Prausnitz 1998, Meek and Fullwood 2001), appears not 
to be rate limiting.  However, larger particles (500 and 1000 nm) have more 
difficulty crossing this anatomical barrier, such that infusion pressure becomes an 
important parameter and injection success rate decrease significantly.  
Consistent with this hypothesis, statistical analysis in Table 1 shows that 
at a microneedle length of 700 µm, where the most scleral tissue must be 
traversed to reach the suprachoroidal space, success rate depended strongly on 
particle size. Using 800 and 900 µm microneedles, particles smaller than the 
collagen fiber spacing (20 and 100 nm) behaved similarly and particles larger 
than the collagen fiber spacing (500 and 1000 nm) also behaved similarly, but 
there was a significant difference between 100 nm and 500 nm particles. The 
longest microneedles (1000 µm), which probably reach the base of the sclera, 
showed no significant dependence on particle size, suggesting that overcoming 
the collagen barrier in the sclera was no longer needed.  
Table 4.1.1 Statistical comparison of injection success rates of 
particles of different sizes at different microneedle lengths. Values 
in the table are p values determined using ANOVA. Statistical 
significance between particle sizes at a given microneedle length 
















700 µm 0.02* 0.02* 0.09 0.02* 
800 µm 0.37 0.00* 0.10 0.01* 
900 µm 0.18 0.03* 0.18 0.03* 
1000 µm 0.18 0.37 0.21 0.18 
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Our hypothesis further suggests that particles of 20 and 100 nm can 
spread within the sclera as well as the suprachoroidal space, whereas particles 
of 500 and 1000 nm should localize exclusively in the suprachoroidal space. In 
Figure 4.1.6, we compare the spread of 20 nm particles to 1000 nm particles 
under identical conditions. As expected, the smaller particles exhibited significant 
spread in the sclera as well as the suprachoroidal space (Figure 4.1.6a). In 
contrast, the larger particles are relegated primarily to the suprachoroidal space 
and are largely excluded from the sclera (Figure 4.1.6b). This localization of large 
particles is also consistent with results shown in Figure 4.1.2, which includes 





Figure 4.1.6 Effect of particle size on particle distribution in the eye. Collaged 
fluorescence microscopy images of tissue cryosections show the delivery of (a) 
20 nm particles and (b) 1000 nm particles into the suprachoroidal space of pig 
eyes ex vivo. The images show that 20 nm particles spread in the suprachoroidal 
space and within the sclera. However, the 1000 nm particles are primarily in the 
suprachoroidal space. The insertion sites are magnified in the insets. Scale bar: 
500 µm. 
 
In summary, 20 and 100 nm particles were reliably injected using a 
minimum microneedle length of 800 µm and a minimum pressure of 250 kPa. To 
deliver 500 and 1000 nm particles, a minimum microneedle length of 1000 µm 
and a minimum pressure of 250 – 300 kPa was necessary. 
 
4.1.4 Effect of Intraocular Pressure 
We predict that an increase in intraocular pressure (IOP) should increase 
the success rate of particle delivery into the suprachoroidal space. To clarify, IOP 
is the internal pressure within the eye that keeps the eye inflated. It provides a 
back pressure that can counteract the infusion pressure. However, our infusion 
pressures of 150 – 300 kPa are two orders of magnitude greater than the mean 
IOP in a normal adult of 15-16 mmHg (~2 kPa) (Klein et al 1992), which means 
that IOP should contribute insignificant back pressure. Instead, we hypothesize 
that the main effect of elevated IOP is to make the sclera surface more firm, 
which reduces tissue surface deflection during microneedle insertion and thereby 
increases the depth of penetration into sclera for a microneedle of a given length. 
In a previous study, we similarly found that tissue deformation in the skin limited 
microneedle insertion depth (Martanto et al 2006).  
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To test this hypothesis, we injected 1000 nm particles at two different 
levels of IOP, 18 and 36 mmHg. Consistent with our hypothesis, delivery success 
rate increased at elevated IOP, as shown in Figure 4.1.7 (ANOVA, p<0.05). 
Notably, at normal IOP, no particles were delivered at the lowest infusion 
pressure (150 kPa) or using the shortest microneedles (700 µm) and only the 
longest microneedles (1000 µm) achieved 100% success rate at the highest 
infusion pressure (300 kPa) (Figure 4.1.7a). In contrast, at elevated IOP, 
particles were sometimes delivered at the lowest infusion pressure and using the 
shortest microneedles, and a 100% success rate was achieved using both 900 
and 1000 µm microneedles at the highest infusion pressure (Figure 4.1.7b). 
Although we did not measure microneedle insertion depth directly, these results 
suggest that microneedle insertion may be more effective at elevated IOP 
because they insert deeper into the sclera and thereby increase infusion success 
rate. 
 
Figure 4.1.7 The effect of infusion pressure and microneedle length on the 
success rate of suprachoroidal delivery of 1000 nm particles at simulated IOP 
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levels of (a) 18 mmHg and (b) 36 mmHg. A total of five infusions were attempted 
at each condition studied. The delivery success rate generally increased with an 
increase in IOP. IOP significantly affected delivery success rate as a function of 





This work introduced a minimally invasive strategy for drug delivery to the 
back of the eye. It showed that a hollow microneedle can inject liquid solution 
and suspensions of particles into the suprachoroidal space of rabbit, pig and 
human eyes ex vivo. Suprachoroidal delivery represents an improvement over 
current periocular and intravitreal delivery methods, both of which are poorly 
targeted to the retinochoroidal sites of most posterior segment diseases. Rather 
than injecting drug outside the eye or in the vitreous humor, microneedle 
technology enables precisely targeted injection within the suprachoroidal space 
of the ocular tunic, which bathes the chorioretinal surface with the drug 
formulation. Moreover, by taking advantage of the unique features of ocular 
anatomy, microneedle injection does not infuse the drug formulation in all 
directions from the injection site as in conventional injections. Instead, by 
targeting the suprachoroidal space, the drug formulation infuses circumferentially 
within the suprachoroidal space to cover a significant area of the back of the eye 
via a single injection.  
This method of delivery has four important attributes of an effective drug 
delivery system for the posterior segment. First, the use of a hollow microneedle 
allows the delivery method to be minimally invasive, because the microneedle 
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only penetrates hundreds of micrometers into the eye, which should protect the 
retina from mechanical damage and reduce the risk of infection.  This is a 
significant improvement over past studies that have accessed the suprachoroidal 
space using much more invasive procedures (Einmahl et al 2002, Gilger et al 
2006, Olsen et al 2006, Kim et al 2007) and may offer a safety profile similar to 
that of conventional intravitreal injection. Second, the suprachoroidal space offers 
the ability to target the choroid and retina by localizing the injection immediately 
adjacent to these tissues. Third, we showed the potential for sustained delivery 
by demonstrating injection of particles up to 1000 nm in diameter into the 
suprachoroidal space. The ability of the suprachoroidal space to accommodate 
particles has not been previously reported. This finding suggests the possibility of 
injecting drug-loaded biodegradable particles into the suprachoroidal space for 
sustained drug release over a period of weeks to months, which could reduce the 
frequency of drug administration. Finally, the inherent safety and simplicity of 
microneedle injection suggest that suprachoroidal delivery could be carried out 
as a straightforward office procedure, rather than the surgical procedures 
required in previous suprachoroidal delivery studies (Einmahl et al 2002, Gilger 
et al 2006, Olsen et al 2006, Kim et al 2007). 
This study further showed that microneedle length, particle size and 
infusion pressure all affect the success rate of particle delivery to the 
suprachoroidal space. Notably, suprachoroidal injection was found to either occur 
fully or not to occur at all for any given injection attempt. This binary (i.e., all or 
nothing) response suggests that a critical event must occur to enable infusion, 
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and we believe that critical event is formation of a pathway from the microneedle 
tip to the suprachoroidal space through the sclera. Because microneedles appear 
to be inserted into, but not fully across the sclera, particles must find a path 
through the remaining scleral tissue to reach the suprachoroidal space. This 
approach is advantageous, because it minimizes mechanical damage to the eye 
and isolates the choroid and retina from the microneedle.  
Our data indicates that smaller particles (20 - 100 nm) can more easily 
flow through scleral tissue because the sieving effect of the sclera’s collagen 
fibers (Jiang et al 2009) allows smaller particles through, but blocks larger 
particles (500 – 1000 nm). The success rate is therefore increased by increasing 
microneedle length, which reduces the amount of scleral tissue between the 
microneedle and suprachoroidal space, and by increasing infusion pressure, 
which provides a greater driving force to push particles through the sclera. 
Increased microneedle length and infusion pressure were especially important for 
larger particles. Although an elevated IOP is not necessary for injection and 
neither is it desirable in patients, we found that elevated IOP also increased 
infusion success rate. We believe that elevated IOP reduced scleral surface 
deflection, which increased microneedle insertion depth and thereby reduced the 
amount of scleral tissue between the microneedle tip and the suprachoroidal 
space.  
In this ex vivo study, we were able to inject volumes of 15 – 35 µL into the 
suprachoroidal space. Larger volumes led to leakage through vortex veins cut 
during excision of the eye from the animal, which we believe is an artifact of the 
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ex vivo model. These volumes are somewhat lower than typical intravitreal 
injections of 50 – 100 µL (Peyman et al 2009). However, previous studies on 
rabbits have shown that the suprachoroidal space can accommodate fluid up to 
several hundred microliters in vivo (Mittl and Tiwari 1987), which is supported by 
our preliminary data using microneedles in rabbits in vivo too (data not shown). 
We therefore conclude that volumes suitable to administer drug doses of use for 
ophthalmic applications can probably be administered using microneedle 
injection into the suprachoroidal space. 
All experiments in this study were conducted on freshly excised animal 
and human cadaver eyes, which is an imperfect model for drug delivery in vivo. 
For example, the conjunctiva was not present on the eyes tested here, because 
the conjunctiva generally detaches once the eye is removed from the orbit. The 
presence of conjunctiva and tear fluid may affect microneedle insertion as 
additional layers the microneedle must penetrate to reach the suprachoroidal 
space. Additionally, the spread of solution and particles in the suprachoroidal 
space may be influenced by choroidal blood flow, which was not present during 
our experiments. For reference, Kim et al. showed that Gd-DTPA, with a 
molecular mass of ~1 kDa, is cleared from the suprachoroidal space within hours 
(Kim et al 2007), which constrains the possibility of sustained drug delivery. 
However, particles are expected to be cleared much more slowly due to their 
much larger size than soluble molecules. Spread of a formulation within the 
suprachoroidal space will also be influenced by the viscosity of the formulation. 
Formulations that are more viscous than the water-like formulation used in these 
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studies will most likely spread less within the suprachoroidal space.  Detailed in 
vivo studies are needed to better understand the spread and clearance 
mechanisms from the suprachoroidal space.  
 
4.1.6 Conclusions  
This work provides the first study to evaluate injection into the 
suprachoroidal space using a microneedle. It shows that this approach offers an 
attractive route to target the posterior segment of the eye in a simple, minimally 
invasive way. Delivery of particle formulations into the suprachoroidal space was 
facilitated by increasing infusion pressure, increasing microneedle length, 
increasing IOP, and decreasing particle size. Injecting particles in this way could 
enable sustained drug delivery from the suprachoroidal space and thereby 
reduce dosing frequency. Finally, this work determined the effect of operating 
parameters on particle infusion, coupled with mechanistic insight into the 
injection process that can be used to design microneedle-based drug delivery 
systems for the suprachoroidal space.  
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4.2 Spread of Injections in the Suprachoroidal Space 
4.2.1 Introduction  
Earlier work has shown that small molecules, particles and even gel 
formulations can be injected into the suprachoroidal space of the eye (Einmahl et 
al 2002, Patel et al 2011). However, the spread and distribution of injected 
materials within the suprachoroidal space has not previously been studied. 
Furthermore, no hollow microneedle device exists which can reliably inject within 
this space in vivo.  A reliable microneedle device may provide a minimally 
invasive way to access the suprachoroidal space as compared to other injection 
procedures (Einmahl et al 2002, Kim et al 2007). A demonstration of such a 
device in an in vivo scenario would provide a valuable tool characterize the 
spread of materials as well as the capabilities of a microneedle based 
administration system.  
In these studies we seek to design a device to reliably inject into the 
suprachoroidal space in vivo and understand the spread of materials injected into 
the suprachoroidal space of rabbit and human eyes. We design the first in vivo 
hollow microneedle device aimed at injecting into the suprachoroidal space of 
rabbit eyes and show that the device can reliably inject into the suprachoroidal 
space of live rabbits in a minimally invasive way. We do so by injecting India ink 
into rabbits, imaging the delivery in multiple ways and quantifying the number of 
successful injections. We show that volumes up to 100 µL can reliably be 
delivered. Furthermore, we quantify the spread of the injected material in the 
suprachoroidal space and demonstrate the spread as a function of volume. The 
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data is further characterized to determine the directionality of the spread within 
the eye.  
 The second half of the study examines the ability of a simple hollow metal 
microneedle device to inject into the suprachoroidal space of fresh human eyes 
ex-vivo. We demonstrate that a microneedle can deliver volumes up to 150 µL 
into the suprachoroidal space of human eyes. The experiments in this study 
simulate in vivo conditions and demonstrate the spread of latex within the 
suprachoroidal space as a function of volume. The study shows that the spread 
is not radial and there is a definite directionality to the spread.  This work 
represents the first study to examine spread within the suprachoroidal space of 
human eyes.  
 
4.2.2 India Ink Spread in the Suprachoroidal Space of Rabbit Eyes In Vivo  
4.2.2.1 Imaging Spread and Hollow Glass Microneedle Device Reliability   
In order to inject into the suprachoroidal space of rabbit eyes in vivo a new 
hollow glass microneedle prototype device was designed. The effectiveness of 
the device was tested by attempting to inject India ink into the suprachoroidal 
space. Of the thirty seven individual injections only two needed to be repeated, 
resulting in a 95 % success rate. The two injections that were not successful 
resulted in no injection at all. There was no accidental delivery into another 
region of the eye.  At no point did the microneedle penetrate further into the 
ocular globe and inject within the vitreous. The two failures can be attributed to 
improper insertion that did not allow the microneedle to insert properly into the 
 72
sclera. Upon repositioning the microneedle and reinserting into the same eye, 
both injections were successful. In some cases where the pupil was large, the 
suprachoroidal injection could be observed visually after enucleating the eye 
from the animal. Figure 4.2.1a shows that by looking through the pupil away from 
the site of injection (arrow). If you look through the pupil away from the injection 
site, the India ink is not visible. As the viewing angle is rotated towards the site of 
injection some dark regions can be viewed (Figure 4.2.1b) and the back of the 
eye looks partially dark and partially light. The dark black color signifies the 
presence of India ink while the light color is without. Looking directly towards the 
site of injection, (Figure 4.2.1c) the whole back of the eye looks dark. 
 
 
Figure 4.2.1 Images showing a view of an India ink injection into the 
suprachoroidal space through the pupil. (a) India ink (black) is not visible in the 
back of the eye when looking away from the injection site (arrow) and as you look 
towards the injection site (b) more India ink can be seen until the back of the eye 
looks completely black (c) In this eye, a hollow glass microneedle, 700 µm in 
length, was used to inject 50 µL into the suprachoroidal space.   
 
Out of all injections, eight (22%) exhibited some amount of reflux through 
the insertion site upon removal of the microneedle. The amount refluxed was not 
quantified but in all cases where there was some reflux, less than 10 µL was 
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refluxed and a significant amount of India ink was still evident in the 
suprachoroidal space eye of the eye. This is in part due to an increase in 
intraocular pressure during the injection. This may be from both the injection of 
the fluid into the suprachoroidal space as well as the pressure applied on the eye 
while the eye is exposed from the socket. The pressure applied on the eye can 
be reduced with a different approach to positioning the eye during injection. This 
may in turn reduce the occurrence of reflux.  A summary of these data is 
provided in Table 4.2.1. All injections took less than 1 minute from time of 
insertion to removal of the microneedle from the eye. The actual injection time 
took less than 20 seconds.  
 
Table 4.2.1 Table of statistics from injections of India ink within the 















30 µL 8 8 (100%) 7 (88%) 
50 µL 23 21 (91%) 17 (74%) 
100 µL 6 6 (100%) 5 (83%) 
Totals 37 35 (95%) 29 (78%) 
 
 
 Suprachoroidal injection success was imaged at two different levels. The 
first was from a macroscopic perspective done by freezing the eye using the 
snap freeze technique. The results showed that the India ink was indeed limited 
to the suprachoroidal space and the spread of the India ink could be clearly seen. 
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Figure 4.2.2a shows the back of the whole eye with the optic nerve in the center. 
The India ink has clearly spread all the way to the back of the eye near the optic 
nerve. The spread of the India ink appears to be confined between the sclera and 
retinal tissues. This is observed by removing the sclera, choroid and retina out of 
the eye as one whole piece and looking at the inside of the back of the eye 
(Figure 4.2.2b). The ‘cup’ of the back of the eye shows that the India ink has 
covered a specific surface area in these tissues. By examining the remaining 
frozen part of the eye, Figure 4.2.c, it is clear that the India ink has not 
penetrated into the vitreous as it is completely clear and free of any black 
pigmentation from the India ink. A thin strip of India ink (II) can be seen around 
the equator   within the remaining tissues of the globe.  An arrow marks the 
injection site (IS) on the sclera.      
 
 
Figure 4.2.2 Images of a frozen rabbit eye after India ink injections into the 
suprachoroidal space. (a) A view from the back of the whole eye shows the India 
ink has reached all the way to the optic nerve, (b) A view of the sclera, choroid 
and retina tissues after they are removed as a cup from the equator. The equator 
(E) is marked with double arrows. This view shows the back of the eye from the 
inside and the India ink within those layers. (c) The vitreous is free from the India 
ink and the injection site (IS) is marked. The India ink (II) can also be seen as a 
ring near the equator (E) in the portion of the eye that is left after removing the 
posterior cup (b). 
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 In order to confirm delivery into the suprachoroidal space at a microscopic 
scale some of the eyes were fixed, cut into sections and stained for histological 
examination. After fixation a section of the eye was easily cut from the eye 
including the sclera choroid and retina just below the injection site. Viewing the 
tissues from the inside the eye clearly shows the India ink within these layers. 
Figure 4.2.3 shows the spread of the India ink in the removed sample and also 
the globe. The sample is nearly all black and the India ink has reached all the 
way to the optic nerve of the eye. Looking in the globe clearly shows a region of 
the eye where there is India ink (dark black region) and where there isn’t (clear 
white region). There is no India ink in the vitreous further confirming that the 
microneedle did not penetrate into the vitreous.  
The histological cross sections also confirmed the localization of the India 
ink to the suprachoroidal space (Figure 4.2.4). The India ink is selectively located 
just between the sclera and choroid layers of the globe. There is no evidence of 
India ink in the retina indicating no penetration of the microneedle deeper than 
the suprachoroidal space.  This data indicates this microneedle device is a 





Figure 4.2.3 A whole rabbit eye after fixation in glutaraldehyde.  A section of the 
globe removed near the injection site is flipped over to reveal the Inida ink (black) 
within the tissues of the globe.  A view of the inside of the eye shows that no 
India ink appears in the vitreous but some can be seen in the remaining tissues 
of the globe.  
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Figure 4.2.4 Histological cross section of the rabbit eye showing India ink within 
the suprachoroidal space. (a) The India ink can be seen in black located between 
the sclera and choroid layers of the eye tissue. Scale bar: 200 µm. (b) A 
magnified view of the India ink in the suprachoroidal space. Scale bar: 25 µm.  
   
4.2.2.2 Quantifying Spread of India Ink in the Suprachoroidal Space 
 We hypothesize that India ink could be spread in the suprachoroidal space 
so as to cover a large area of the chorioretinal surface. In order to determine the 
coverage we injected 30, 50 and 100 µL into the suprachoroidal space and 
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quantified the spread within the space. We also hypothesize that the spread 
would increase with increased volume rather than simply expanding the 
suprachoroidal space and causing increased separation between the sclera and 
choroid layers. In order to test these theories and understand the spread within 
the suprachoroidal space of live rabbit eyes we injected material and 
characterized the delivery in a variety of ways.  
Suprachoroidal injections were performed in the superior temporal 
quadrant of the rabbit eye in vivo. Figure 4.2.5 shows an example of the 
orientation of the rabbit eye relative to the injection site. An asterisk indicates the 
injection site in the right eye of the rabbit and an arrow indicates the direction 
downwards towards the nose. After injection of India ink, the eyes were 
enucleated and the spread of the India ink injected into each eye was digitized.  
Figure 4.2.6 displays all the digitized images of the injections. Each digitized 
image contains an asterisk to indicate the injection site, an arrow pointing to the 
optic nerve, and the letter N indicating the direction downwards towards the 
nose. In both right and left eyes the direction from the injection site to the nose is 
analogous to the direction indicated in Figure 4.2.5.  
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Figure 4.2.5 Injections of India ink were done on live rabbits in the superior 
temporal quadrant of the eye. The eyelids were pushed back to access the 
insertion site (*) more clearly. The image shows the approximate location of the 
injection site (*). It also shows the direction towards the nose (N) indicated by the 





Figure 4.2.6 Digitized distribution of India ink within the suprachoroidal space of 
rabbit eyes. An asterisk indicates the injection site, the arrow points to the 
location of the optic nerve, and the letter N indicates the direction towards the 
nose. Scale bar: 5 mm.  
 
Qualitative analysis of the spread from these images shows the  India ink 
does not flow uniformly from the injection site; i.e. it does not spread in a radial 
fashion from the site and there appears to be some directionality to the flow. We 
hypothesize this directionality is not dependant on the microneedle but instead 
on the anatomy of the eye. The injection was done in the same quadrant of the 
rabbit eye, superior temporal, on both right and left eyes. Overall the India ink 
travels laterally towards the nasal direction along the limbus more than the 
opposing direction. This is more dramatic in the 100 µL injection images since 
the large volume causes the discrepancy between the two directions to be more 
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obvious. This is also confirmed quantitatively by calculating the ratio of the max 
distance towards the nose versus the opposing direction from the injection site. 
The ratios are 3.4±0.4, 2.3±1.1, 6.2±0.7 for 30, 50 and 100 µL respectively.  The 
images also reveal that the injection stops abruptly at the limbus and does not 
move further towards the anterior segment of the eye. The injection site was 
chosen to be approximately 3-4 mm posterior to the limbus and calculations of 
the furthest distance the India ink traveled towards the anterior segment shows 
that it does not move beyond the limbus. The maximum distance anterior is 
2.2±0.4, 2.8±0.4, 2.7±0.3 for 30, 50 and 100 µL respectively. This phenomenon 
is clearly seen after the eye is enucleated (Figure 4.2.3). This may be due to the 
dense cilliary processes and muscles present near the limbus that prevent 
expansion of the tissues. As a result, the limbus serves as a natural barrier that 
does not allow fluid within the suprachoroidal space to flow into the anterior 
segment. In addition since the limbus region is facilitates uveal scleral outflow of 
aqueous humor from the anterior chamber of the eye into the suprachoroidal 
space it may not allow flow in the opposing direction.   
We hypothesize that volumes up to 100 µL of India ink injected into the 
suprachoroidal space will not simply accumulate in a confined area within the 
suprachoroidal space but spread further into unoccupied areas as more volume 
is injected. This appears to be true qualitatively (Figure 4.2.8) but in order to 
prove this we calculated and compared the choroiretinal surface area covered by 
each injection. The total area covered was calculated from each injection’s 
digitized image.  Figure 4.2.7 shows that as the volume of India ink injected 
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increases the surface area covered increases as well. On average the delivery of 
30, 50 and 100 µL resulted in coverage of 113±15, 175±26 and 249±25 mm2 of 
the choroiretinal surface, respectively. These values are statistically different 
from each other (ANOVA p<0.05) indicating that the India ink is spreading into 
uncovered portions of the suprachoroidal space as more volume is injected.  
 
 
Figure 4.2.7 A graph showing the surface area covered from 30, 50 or 100 µL (x-
axis) of India ink injected in the suprachoroidal space in vivo in rabbits using a 
glass microneedle. The chorioretinal surface area (left y-axis) covered increases 
with increasing volume. The surface area per volume of India ink (right y-axis) 
injected decreases as the volume injected increases. A minimum of n=3 
injections were performed for each volume and standard deviations are shown. 
 
 We further hypothesize that as the volume of an injected fluid within the 
suprachoroidal space increases it will not only spread within unoccupied regions 
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of the suprachoroidal space but it will also cause an expansion of the 
suprachoroidal space. Our theory is that since this is a virtual space, it will allow 
the sclera and choroid to separate further from each other to accommodate the 
additional fluid.  In order to show this was occurring with our India ink injections 
we further characterized the spread of India ink by normalizing the chorioretinal 
surface area covered by the volume injected. Figure 4.2.7 shows the surface 
area covered per volume is 3.8±0.2, 3.5±0.2 and 2.5±0.4 mm2/ µL for 30, 50 and 
100 µL respectively. The graph shows this normalized value drops as the volume 
is increased.  
 If the additional volume injected was simply expanding into unoccupied 
regions of the suprachoroidal space, then the surface area per volume would 
remain constant. If however, the additional volume was causing an expansion of 
the suprachoroidal space then this value should drop because the fluid is 
incompressible. Statistical analysis shows that the normalized values for 30 and 
50 µL are the same but the value for 100 µL is statistically different from both 30 
and 50 µL (ANOVA p<0.05). This implies that an increase in injected volume 
from 30 to 50 µL does not cause the suprachoroidal space to expand much 
more. Instead the additional 20 µL spreads into new unoccupied regions of the 
suprachoroidal space. However, when the injected volume is increased from 50 
to 100 µL the suprachoroidal space does expand to hold the additional 50 µL. In 
order to make this more explicit the approximate thickness of the expanded 
suprachoroidal space for each of these normalized values was determined to be 
270±38, 291±38 and 405±40 µm for 30, 50 and 100 µL respectively.  
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We hypothesize that since the suprachoroidal space is a virtual space in 
the posterior segment of the eye that can easily expand to hold fluid, 
suprachoroidal injections should be able to cover a large percentage of the 
choroiretinal surface area of the eye. To determine what fraction of the available 
surface area a single microneedle injection could cover we assumed the 
maximum surface area available in the back of the eye as the area of the sclera. 
The percentage area covered by injections of India ink was calculated by dividing 
the area of the India ink injections by the maximum surface area available. Figure 
4.2.6 shows the percentage of the back of the eye that was covered by 30, 50 
and 100 µL was 17±2, 26±4 and 36±4 %, respectively. The graph shows that the 
percent covered increases with increasing volume (ANOVA p<0.05) and a single 
injection of 100 µL can cover nearly 36 % of the available area. The 
suprachoroidal space of the rabbit eye may be able to accommodate even more 
than 100 µL. However, additional volume may cause the space to expand in 
thickness and limit the additional volume of fluid from spreading into new regions 
of the suprachoroidal space that are not already occupied by the injected 
formulation.    
  




Figure 4.2.8 A graph showing the percentage surface area covered from a 
microneedle injection of India ink in the suprachoroidal space in vivo in rabbits. 
The percent area is on the y-axis and the volumes injected on the left. Error bars 
represent standard deviations. Each value is statistically different (ANOVA 
p<0.05) from each other indicating that the percent covered is increasing with 
increasing volumes.  
 
 In order to characterize the directionality of the injections we determined 
the maximum spread of India ink in two directions: (1) distance from the limbus 
towards the optic nerve and (2) the total lateral distance parallel to the limbus. 
The first represents the ability of the India ink to move further to the back of the 
eye and the second represents the ability of the India ink to spread around the 
eye along the equator. In all thirteen injections the India ink was able to reach the 
back of the eye, i.e. the optic nerve as shown in Figure 4.2.6. Even at the 
smallest injection volume, 30 µL, the India ink reached the optic nerve. Figure 
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4.2.9 summarizes the analysis of the directionality of the spread. The y-axis 
represents the maximum distance traveled in the two directions and the x-axis 
shows the two directions measured. The asterisks indicate the distances that are 
statistically significant between the different injection volumes (ANOVA p<0.05). 
On average the maximum distance the India ink traveled towards the optic nerve 
and the back of the eye was 11±1.6, 15±2.0, and 13±2.1 mm for 30, 50 and 100 
µL injections, respectively.  There was only a statistical difference between 30 
and 50 µL indicating that the additional volume after 50 µL did not really cause 
the India ink to spread further in the back of the eye. The average distance 
covered laterally in parallel to the limbus was 16 ± 3.8, 19 ± 5.5, and 27 ± 1.2 mm 
for 30, 50 and 100 µL injections, respectively. The lateral distances for 30 and 50 
µL injections were not statistically different but for the 100 µL injection the lateral 
distance was statistically different from the other two. This is indicates that after 
50 µL there is significant spread in the lateral direction. Putting these two pieces 
of information together implies that Injecting 30 and then 50 µL causes the India 
ink to spread towards the back of the eye and does not spread much further 
since it has reached the optic nerve. The additional volume injected, up to 100 µL 
total, causes the spread to occur around the eye and also expands the 




Figure 4.2.9 Graph showing the distance covered from a microneedle injection of 
different volumes of India ink in the suprachoroidal space of rabbit eyes in vivo. 
The y-axis represents the maximum distance traveled in the two directions and 
the x-axis shows the two directions measured. The max distance towards the 
optic nerve is the maximum distance the India ink covers from the limbus to the 
back of the eye. The max lateral distance is the maximum total distance the India 
ink covers parallel to the limbus (i.e. around the eye) The asterisks indicate the 





4.2.3 Spread of Latex in Human Eyes Using Hollow Metal Microneedles 
  We hypothesize that our hollow metal microneedles would be able to 
inject formulations into the suprachoroidal space of human eyes in a simulated in 
vivo experimental setup. We further hypothesize that the microneedles would be 
able to reliably inject volumes up to 150 µL and be able to cover a significant 
portion of the back of the eye. In order to test this we developed a procedure to 
visualize the spread of a formulation delivered within the suprachoroidal space.  
The procedure involved injecting latex into human eyes, snap freezing the whole 
eye and dissecting it in a way so as to preserve the injected latex on the inside 
part of the sclera where it could be imaged and quantified. We used this 
procedure to inject human eyes with a latex formulation and quantified the 
spread of the latex in the suprachoroidal space. We chose to perform these 
experiments on eyes that were freshly enucleated from humans. The reason for 
choosing this condition was to preserve as much as possible the structure and 
arrangement of the layers of the eye.  In addition, we induced an intraocular 
pressure of 15 mm Hg to simulate the pressure in a living eye. The insertion site 
was located 8 mm posterior to the limbus. This distance was chosen since it 
would be accessible on an actual patient using a microneedle. A summary of the 
eyes used and injection parameters are listed in Table 4.2.2.  
 
Table 4.2.2 Table showing the characteristics of the human eyes 
used and the experimental parameters tested. The eyes were 
obtained as quickly as possible from the time of death. The longest 















1  9:20 14:57 5:37 50
2  7:31 15:23 7:52 50
3  12:17 17:15 4:58 50
4  9:20 15:07 5:47 100
5  7:31 15:17 7:46 100
6  12:17 17:20 5:03 100
7  2:49 10:04 7:15 150
8  12:29 16:23 3:54 150
9  12:29 16:24 3:55 150
 
 
A single hollow metal microneedle was able to inject volumes up to 150 µL 
into the suprachoroidal space. The eye was frozen and the globe was dissected 
using a blade, into “petals” starting from the optic nerve. The cuts were made up 
to the cornea leaving the cornea intact. The petals were opened up from the optic 
nerve. The petals contained the tissues of the globe (sclera, choroid and retina) 
and exposed the vitreous inside as a frozen white ball. The vitreous was 
removed carefully leaving the globe tissues and anterior segments of the eye. 
The petals were laid flat with the cornea in the center and the choroid and retina 
were slowly pulled away. This left behind latex (pink in color) on the sclera that 
could be easily distinguished from the white sclera with the transparent cornea in 
the center of the petals. Figure 4.2.3 shows representative images of the different 
volumes injected after this procedure has been performed. The surface area 
could then be quantified from the images by determining the area that the pink 
latex covered. The total area could be determined by calculating the area of the 




Figure 4.2.10 Representative images of the spread of latex in the suprachoroidal 
space after injection of (a) 50 µL, (b) 100 µL, and (c) 150 µL using a hollow metal 
microneedle. The white petals are the sclera with pink latex on top of them. 
Some of the sclera is pigmented (b) and is darker than others. The choroid and 
retina have been removed and the cornea is in the center. The injection site is 
marked with an asterisk. Scale bar: 10 mm.  
 
We hypothesize that there may be a maximum chorioretinal surface area 
that a single microneedle injection of latex can cover. In order to determine this 
we determined the surface area coverage from injections of up to 150 µL of latex.  
The injections resulted in coverage of 257 ± 50, 432 ± 105 and 439 ± 6 mm2 area 
of the back of the eye for from 50, 100, and 150 µL respectively. The data 
suggest that the spread of latex increases with an increase in volume from 50 to 
100 µL however, further increase in volume does not result in a substantial 
increase in area. Statistical analysis (ANOVA p<0.1) confirmed that the areas 
corresponding to 50 and 100 µL were different but there was no difference in 100 
and 150 µL areas. In order to confirm that this was not simply a result of a 
difference in the sizes of the eyes or available area, the percent coverage was 
calculated by normalizing the areas to the total available area for injection. These 
areas correspond to 17 ± 4, 39 ± 10 and 40 ± 1 % of the total area available in 
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the back of the eye. Statistical analysis (ANOVA p<0.1) confirmed that the 
percentages corresponding to 50 and 100 µL were different but there was no 
difference in 100 and 150 µL percent areas (Figure 4.2.11). However, these data 
do show that a single microneedle injection of 100 or 150 µL could cover 




Figure 4.2.11 Graph showing the surface area covered from a single 
microneedle injection of latex in the suprachoroidal space of fresh human 
cadaver eyes The x-axis displays the volume delivered. The surface area 
covered (diamond markers) show the surface area covered using the left y-axis. 
The surface area per volume of fluid (square markers) is plotted against the right 





Figure 4.2.12 Graph showing the percent area covered from a microneedle 
injection of latex in the suprachoroidal space of fresh human cadaver eyes. Error 
bars are standard deviations.  
 
 We further hypothesize that as the volume of latex injected within the 
suprachoroidal space increases it will not only spread within unoccupied regions 
of the suprachoroidal space but it will also cause an expansion of the 
suprachoroidal space. Our theory is that since this is a virtual space, after some 
threshold volume the suprachoroidal space may expand in thickness 
significantly.  In order to determine this value with latex injections we further 
characterized the spread of India ink by normalizing the chorioretinal surface 
area covered by the volume injected. Figure 4.2.11 shows the surface area 
covered per volume is 6.3 ± 1.0, 4.9 ± 1.1 and 2.9 ± 0.1 mm2/µL for 50, 100 and 
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150 µL respectively. The graph shows this normalized value drops as the volume 
is increased.  
 If the additional volume injected was simply expanding into unoccupied 
regions of the suprachoroidal space, then the surface area per volume would 
remain constant. If however, the additional volume was causing an expansion of 
the suprachoroidal space then this value should drop because the fluid is 
incompressible. Statistical analysis shows that the normalized values for 50 and 
100 µL are the same but the value for 150 µL is statistically different from both 50 
and 100 µL (ANOVA p<0.1). This implies that an increase in injected volume 
from 50 to 100 µL does not cause the suprachoroidal space to expand more. 
Instead the additional 50 µL spreads into new unoccupied regions of the 
suprachoroidal space. However, when the injected volume is increased from 100 
to 150 µL the suprachoroidal space does expand to hold the additional 50 µL. In 
order to make this more explicit the approximate thickness of the expanded 
suprachoroidal space for each of these normalized values was determined to be 
200±35, 243±69 and 341±5 µm for 50, 100 and 150 µL respectively.  
 In order to characterize the directionality of the injections we determined 
the maximum spread of latex in two directions: (1) distance from the limbus 
towards the optic nerve and (2) the total lateral distance parallel to the limbus. 
The first represents the ability of the India ink to move further to the back of the 
eye and the second represents the ability of the India ink to spread around the 
eye along the equator. Figure 4.2.13 summarizes the analysis of the directionality 
of the spread. The y-axis represents the maximum distance traveled in the two 
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directions and the x-axis shows the different volumes injected. The asterisks 
indicate the distances that are statistically significant between the different 
injection volumes (ANOVA p<0.1). On average the maximum distance the latex 
traveled towards the optic nerve and the back of the eye was 15±2.0, 17±1.3, 
and 15±0.3 mm for 50, 100 and 150 µL injections, respectively.  There was a 
statistical difference between 50 and 100 µL injections as well as 100 and 150 µL 
injections but not between 50 and 150 µL injections. This indicates that there 
may be some variability in the distance the latex traveled towards the back of the 
eye but delivering as much as 150 µL did not cause the latex to spread further 
back than a 50 µL injection. The average distance covered laterally in parallel to 
the limbus was 15 ± 3.8, 20 ± 8, and 24 ± 1.5 mm for 50, 100 and 150 µL 
injections, respectively. On average there was an increase in the lateral distance 
spread around the limbus but neither 50 nor 150 µL injection distances were 
statistically different from 100 µL injections.  This may be due to the high degree 
of variability in the 100 µL injections. However there was a difference between 50 
and 150 µL injections indicating a significant increase in spread in the lateral 
direction by increasing the volume from 50 to 100 µL. Putting these two pieces of 
information together implies that injecting volumes in excess of 50 µL may not 
cause the spread of latex towards the back of the eye to increase much, but does 
cause the spread around the eye to increase.  
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Figure 4.2.13 Graph showing the distance covered from a microneedle injection 
of latex in the suprachoroidal space of human cadaver eyes. The y-axis 
represents the maximum distance traveled in the two directions and the x-axis 
shows the two directions measured. The max distance towards the optic nerve is 
the maximum distance the latex covers from the limbus to the back of the eye. 
The max lateral distance is the maximum total distance the latex covers parallel 
to the limbus (i.e. around the eye). The asterisks indicate the distances that are 
statistically significant between the different injection volumes (ANOVA p<0.1).  
 
4.2.4 Discussion 
 This study represents the first study to examine the capability of a hollow 
microneedle to inject within the suprachoroidal space of a live animal eye. The 
first part of the study showed that a prototype hollow glass microneedle device 
could reliably inject India ink into the suprachoroidal space of rabbits in vivo.  The 
India ink study showed that volumes up to 100 µL could be delivered into the 
rabbit eye and the India ink is well localized to the suprachoroidal space. The 
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coverage of the chorioretinal surface from suprachoroidal injections of India ink 
was determined and this data showed that up to 36 % of the available surface 
could be covered from a single microneedle injection of 100 µL. Further 
characterization of the spread showed the India ink reaches the optic nerve in the 
back of the eye with a volume as small as 30 µL and further injections do not 
cause the spread to occur further back but instead in the lateral direction around 
the eye. In addition, the analysis showed that volumes in excess of 50 µL can 
cause the suprachoroidal space to expand in thickness and these thicknesses 
are on the order of several hundred micrometers.  
 The second half of the study examined the ability of a metal hollow 
microneedle device to inject latex within the suprachoroidal space of fresh human 
cadaver eyes. The work showed that it was possible to inject up to 150 µL of 
latex in to the suprachoroidal space and cover up to 40 % of the chorioretinal 
surface. In addition, the injections were performed at a site that would be 
accessible on a human (8 mm posterior to the limbus) and the results show that it 
is possible to inject in the suprachoroidal space from such a site.  In addition the 
volumes injected represent volumes that are currently being injected into the 
vitreous for treatment of diseases such as AMD. As a result, this shows that it 
would be theoretically possibly to inject a comparable dose into the 
suprachoroidal space.  
 The latex study implies that there may be a maximum available surface 
area that a single microneedle injection can cover. The available surface area 
covered by 100 and 150 µL was nearly identical, 40 %, but the variability for the 
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two volumes was quite different. For 100 µL the standard deviation was 10 % 
while for 150 µL it was only 1 %. This suggests that a sufficient volume is needed 
to fill out the maximum available area after which the additional volume causes 
the thickness of the suprachoroidal space to expand.  In the case of latex in 
these human cadaver eyes that area may be near the 40 % of the available area, 
approximately 440 mm2. Until that area if properly filled the variability may be 
high, as is the case with 100 µL, and as it gets filled out, this variability 
decreases. Somewhere between 100 and 150 µL the maximum available surface 
area may be sufficiently filled and as a result the 150 µL variability is low. This is 
also consistent with the variability seen in the calculation of the thickness of the 
suprachoroidal space. The standard deviation for 50 and 100 µL thicknesses was 
35 and 67 µm while for 150 µL it was only 5 µm. In the case of the India ink study 
in rabbit eyes this limit may not have been reached and as a result a similar trend 
is less explicit.    
 What this further implies is that a single microneedle injection may not be 
able to fill all of the available suprachoroidal space. The resistance to flow further 
into unoccupied regions of the suprachoroidal space versus the resistance to 
expand the thickness of the suprachoroidal space may be too large. The primary 
force to overcome for expansion of the space may simply be the intraocular 
pressure. However it is unclear if the connections of the between the 
suprachoroidal space and its neighboring tissues, the sclera and choroid, vary 
significantly in location in the eye.  As a result, in order to properly understand if 
this limit exists and if it is dependent on the anatomy of the eye further studies 
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need to be done to explore the makeup of the suprachoroidal space, variations in 
location and the balance of forces in the eye that control the expansion of the 
suprachoroidal space.      
 The prototype devices tested for injecting into the suprachoroidal space in 
this study showed consistent delivery into the suprachoroidal space. Both the 
hollow glass and metal microneedle devices performed well under the laboratory 
conditions, however additional modifications need to be made for this method to 
be applicable for human clinical practice. During the initial tests of the metal 
microneedle injection, one insertion (out of a total of 16) resulted in an intravitreal 
injection.  This may have occurred because of a combination of a thin sclera and 
long microneedle. The microneedle may have been longer than was needed to 
be to reach the base of the sclera and as a result penetrated into the vitreous. 
Since human sclera thickness can vary between patients and location on the 
eye, it would be convenient to measure tissue thickness at the site of injection 
and adjust microneedle length or select and appropriately sized microneedle to 
ensure successful delivery. An automated insertion and infusion method may 
also increase the chances of successful deliveries. An insertion method 
incorporating a feedback system when the needle has inserted properly into the 
sclera and that infuses the fluid slowly into the suprachoroidal space may also 
reduce the occurrence of reflux from the eye. The current design shows promise 
in a research setting and improvements such as these may make the device 
more reliable and safe for human testing.        
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The spread of latex within the suprachoroidal space of fresh human eyes 
revealed some valuable information about what to expect from an injection using 
a hollow microneedle. Although the latex formulation is not the ideal material to 
inject within the suprachoroidal space, it did demonstrate that it is possible to 
inject volumes up to 150 µL. Since most intravitreal injections are either 50 to 100 
µL in volume, this shows that a suprachoroidal injection is capable of 
administering a dose similar to that of an intravitreal injection (Peyman et al 
2009). It also showed that injections of 50 µL resulted in the latex moving back a 
maximum distance of approximately 15 mm from the limbus and this value did 
not change much with additional volumes up to 150 µL. Instead the additional 
spread was around the eye; i.e parallel to the limbus and equator. It seemed 
apparent that the resistance for latex to move in the suprachoroidal space is less 
around the equator than it is towards the posterior direction. These results imply 
that in order to get a drug all the way to the optic nerve or macula of a human 
eye it will be important to study the anatomy and physiology of the 
suprachoroidal space, the effects of formulation properties on spread within the 
space and also how injections and device design influence the spread.  
Both the rabbit and human eye study only examined the immediate spread 
from an injection into the suprachoroidal space. In an in-vivo situation the 
injected formulation may spread further in the suprachoroidal space over time. 
Dynamic transport mechanisms and flow may alter the spread of injected 
formulations from within the suprachoroidal space causing them to spread in 
different directions or may actually clear material from within the space. As an 
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example, the uveoscleral drainage routes for the aqueous humor may cause flow 
to occur from the anterior of the eye towards the posterior through the 
suprachoroidal space. This bulk flow may also cause an injected drug to be 
transported out of the suprachoroidal space. .  
4.2.5 Conclusion  
 This study showed that it is possible to inject up to 100 µL in vivo in rabbits 
and 150 µL ex vivo in human eyes targeting the suprachoroidal space. The work 
also showed that the prototype devices used to inject into the suprachoroidal 
space could do so reliably. These injections also showed that the spread of the 
material increases in the lateral direction as more volume is injected rather than 
the posterior direction. Furthermore, a single injection can cover up to 40 % of 
the back of the human eye. Overall this work showed that a single hollow 
microneedle can reliably deliver therapeutically relevant volumes of fluid into the 
suprachoroidal space and cover a large percentage of the chorioretinal surface.  
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4.3 In Vivo Ocular Clearance of Molecules and Particles  
 
4.3.1 Introduction 
An effective ocular drug delivery system for the back of the eye should be 
able to provide targeted and sustained delivery to its target tissues, the choroid 
and retina, in a minimally invasive way. In our initial work we have shown that a 
hollow microneedle has the ability to inject a variety of materials into the 
suprachoroidal space. The ability to inject particles shows the potential to provide 
sustained delivery. However, the in-vivo kinetics of molecules and particles in the 
suprachoroidal space have not been studied. In this work we examine the ability 
of a hollow microneedle to inject a variety of materials into the suprachoroidal 
space and examine the clearance kinetics of these materials.  
We aim to test two things: (1) determine if suprachoroidal delivery is more 
targeted to the choroid and retina tissues than currently practiced intravitreal 
delivery and (2) determine if particles delivered into this space have long 
residence times so they can provide sustained delivery to the choroid and retina. 
To address these questions, this work shows that sodium fluorescein injected 
into the suprachoroidal space is well localized to the back of the eye and does 
not expose the lens to the drug, whereas an intravitreal injection shows no 
apparent targeting to the chorioretinal tissues in the back of the eye. This study 
examines small molecule and macromolecule residence times and shows that 
both clear the suprachoroidal space on a timescale that is on the order of hours. 
As a result proper formulations are necessary for controlled or sustained delivery 
from this space. We demonstrate that if particles are injected into the 
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suprachoroidal space, they can remain in this space on the time scale of months. 
This could enable sustained or controlled drug delivery from within the 
suprachoroidal space. This is the first study to examine the capability of 
suprachoroidal delivery to provide targeted delivery to the eye and examine the 
kinetics of particles within the suprachoroidal space.  
 
4.3.2 Comparison of Suprachoroidal and Intravitreal Injections  
In order to compare the intraocular distribution profile of suprachoroidal 
and intravitreal injections, sodium fluorescein was injected into both locations and 
the fluorescence intensity in the eye was monitored over time. A 600 µg/mL 
solution was used for suprachoroidal injection with a 700-800 µm length hollow 
microneedle, and a 6 µg/mL solution was injected into the vitreous using a 
standard 30 gauge needle. Identical volumes, 50 µL, were injected in both 
scenarios. The difference in concentration of the sodium fluorescein is due to the 
sensitivity of the machine to detect the fluorescence within and between tissues 
versus what it can detect in transparent media such as vitreous and aqueous 
humor in the eye. The goal of this experiment was to compare the distribution 
profile of sodium fluorescein in the eye, determine the half life of the fluorescein 
in each injection site, and the ability to target the choroid and retina 
(chorioretinal) layers of the eye from each type of injection.  
An initial baseline scan was performed on all eyes prior to injecting any 
formulation (Figure 4.3.1).  A baseline scan provided the fluorescence intensity 
within the visual axis of the eye. The position of eye tissues are estimated from 
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peaks observed in the baseline scan. The peak to the furthest left, near position 
20, is the retina while the two peaks at the furthest right, near position 110, are 
the cornea. Just to the left of the cornea are two additional peaks, near position 
90, which demarcate the lens. The positions in between the lens and the retina 
can be approximated to be the vitreous. The position of these tissues may not be 
exactly the same with each scan, even among the same eye, but will be relatively 
in the same position. As a result the baseline scan provides the reference point 
for future scans about the location of these tissues.  
 
 
Figure 4.3.1 Representative baseline scan of the rabbit eye in vivo with no 
injection. The baseline profile was obtained from a single scan of the eye along 
the visual axis. The x-axis, position, represents the visual axis of the eye while 
the y-axis shows the measurement of the fluorescent intensity at that position. 
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The position of eye tissues are estimated from peaks observed in the baseline 
scan. The peak to the furthest left is the retina while the two peaks at the furthest 
right are the cornea. Just to the left of the cornea are two additional peaks which 
demarcate the lens.   
 
 Intravitreal injection profiles showed that the sodium fluorescein 
distributes itself fairly uniformly within the vitreous and remains primarily in the 
vitreous (Figure 4.3.2). Within 30 minutes after injection a broad peak is seen 
throughout the vitreous and within 1 hour the maximum concentration is reached 
within the vitreous as it distributes itself throughout the vitreous chamber. After 
the 1 hour time point the concentration profile is fairly uniform within the vitreous.  
These levels drop off uniformly in the subsequent hours. Within 24 hours the 
levels in the eye have returned to baseline levels indicating the fluorescein was 
no longer detectable in the eye (Figure 4.3.2). The calculated half life of 
fluorescein based on a first order kinetic fit to the concentration within the 
midvitreous for each eye was 2.4±0.2 hours. The average concentration in the 





Figure 4.3.2 Representative concentration profiles of sodium fluorescein in the 
rabbit eye in vivo over time after an intravitreal injection of 50 µL using a 30 g 
needle. Each profile was created from a single scan of the eye along the visual 
axis. The x-axisx-axis, position, represents the visual axis of the eye with the 
cornea located to the right of the x-axis in the anterior segment. The approximate 





Figure 4.3.3 Average concentration of sodium fluorescein in the vitreous over 
time after an intravitreal injection of 50 µL (6 µg/mL) using a 30g needle. The 
concentration drops over time and the fluorescein is cleared from the vitreous 
within 24 hours after injection. (n=3 and error bars are standard deviations).   
 
 
The distribution profile for a suprachoroidal injection of sodium fluorescein 
showed a dramatically different result than the intravitreal injection profile (Figure 
4.3.4). Within 5 minutes after injection a sharp peak developed in the 
suprachoroidal space that dropped off quickly in the surrounding tissues. Over 
time this peak remained in the suprachoroidal space with significantly lower 
levels in the vitreous. The concentration dropped quickly within the first few hours 
but still remained lower in the vitreous than in the suprachoroidal space. The 
profiles indicate no significant transport of sodium fluorescein into the vitreous or 
anterior segment. Similar to an intravitreal injection, within 24 hours the sodium 
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fluorescein concentration returned to baseline levels indicating the fluorescein 
had cleared the suprachoroidal space (Figure 4.3.4). The calculated half life of 
fluorescein based on a first order kinetic fit to the concentration within the 
suprachoroidal space for each eye was 1.2±0.1 hours. Figure 4.3.5 shows the 
average concentration of sodium fluorescein in the suprachoroidal space over 
time.     
 
Figure 4.3.4 Representative concentration profiles of sodium fluorescein in the 
rabbit eye in vivo over time after a suprachoroidal injection of 50 µL using a 
microneedle. Each profile was created from a single scan of the eye along the 
visual axis. The x-axis, position, represents the visual axis of the eye with the 
cornea located to the right of the x-axis in the anterior segment. The approximate 
position of eye tissues is estimated from baseline scans of the eye. The arrow 






Figure 4.3.5 Average concentration of sodium fluorescein in the suprachoroidal 
space over time after a suprachoroidal injection of 50 µL (600 µg/mL) using a 
microneedle. The concentration drops over time and the fluorescein is cleared 
from the vitreous within 24 hours after injection. (n=3 and error bars are standard 
deviations).  
 
 We hypothesize that suprachoroidal delivery can target the chorioretinal 
tissues in the back of the eye more effectively than an intravitreal injection. In 
order to quantify this we compared levels of fluorescein near the target 
choroid/retina tissues to the level at the lens. For intravitreal injections, the ratio 
of fluorescence intensity at the vitreous/retina interface to the vitreous/lens 
interface was determined. For a suprachoroidal injection we calculated the ratio 
of the fluorescence intensity in the suprachoroidal space to the intensity at the 
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lens. With these definitions, a large ratio indicates more effective targeting to the 
chorioretinal tissues in the back of the eye. The values were then plotted over 
time and compared in Figure 4.3.6. The ratio for an intravitreal injection hovers 
near 1 for all times post injection and for most time points is actually below 1. 
This indicates that the fluorescein distributes throughout the vitreous fairly evenly 
and there is no selectivity towards the back of the eye where the retina is located. 
In contrast, the ratio for suprachoroidal injections at baseline is 4.2 ± 0.8 and 
immediately after injection this ratio jumps to 214 ± 116 since the injection 
spreads the formulation within the suprachoroidal space to the back of the eye 
within minutes. This ratio falls as time goes on but always remains above 10. The 
ratio is higher for all time points post injection from a suprachoroidal injection as 
compared to an intravitreal injection (ANOVA p<0.05).  As a result, a 
suprachoroidal injection is better at targeting the fluorescein to the chorioretinal 





Figure 4.3.6 Graph showing the ratio of concentrations of sodium fluorescein 
within two locations in the eye after intravitreal (squares) and suprachoroidal 
injections (triangles). The ratio represents the ability of the injection to target the 
chorioretinal tissues. For an intravitreal injection the ratio is the concentration in 
the vitreous near the retina to that near the lens. For a suprachoroidal injection 
the ratio is the concentration in the suprachoroidal space to the concentration in 
the vitreous near the lens. The graph shows that the ratio is higher for a 
suprachoroidal injection and is statistically different at all time points after 
administration than an intravitreal injection. Error bars are standard deviations. 




4.3.3 Injection of Macromolecules in to the Suprachoroidal Space 
 In addition to a small molecule such as fluorescein, we wanted to 
investigate the capability of a hollow microneedle to inject proteins and other 
macromolecules within the suprachoroidal space. As a result we injected 40 kDa 
and 250 kDa dextran tagged with FITC (fluorescein isothiocyanate) within the 
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suprachoroidal space. We also investigated the ability to inject a therapeutic 
antibody, bevacizumab (Avastin®), tagged with Alexa Fluro 488 within the 
suprachoroidal space. This antibody is a therapeutically relevant 147 kDa 
macromolecule since it is an anti vascular endothelial growth factor (VEGF) that 
has been used to treat patients with wet macular degeneration (Chappelow and 
Kaiser 2008). We hypothesize that macromolecules can be successfully targeted 
to the suprachoroidal region and will have similar localization as sodium 
fluorescein injected within the suprachoroidal space. Two eyes were injected for 
each macromolecule and the fluorescence intensities in the eyes were monitored 
over time.  
The distribution profiles from suprachoroidal injections showed a sharp 
peak in the suprachoroidal space with a quick drop off in surrounding regions. As 
time progressed this peak dropped in value but maintained its shape (Figures 
4.3.7-9). Overall the profile shapes are similar to sodium fluorescein and showed 
similar localization. The ratio of suprachoroidal levels as compared to levels in 
the lens for each of the macromolecules were above 25 up to 6 hours from time 
of injection. Immediately after injection the ratio was 224±101, 89±20, and 98±68 
for 40kDa dextran, 250 kDa dextran and bevacizumab respectively. This 
indicates the injection was well targeted to the chorioretinal tissues in the back of 
the eye with minimal exposure to the front of the eye. Within 24 hours the 
fluorescence intensity of the 40 kDa dextran had reached near baseline levels. 
The level of the 250 kDa and dextran and bevaciszumab were slightly above 
baseline levels (Figures 4.3.10-12). This indicated that the macromolecules were 
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cleared from the suprachoroidal space in approximately 24 hours. The calculated 
half lives of 40kDa dextran, 250 kDa dextran and Avastin in the suprachoroidal 
space were 3.6±0.5, 5.6±1, and 7.9±0.5 hours respectively.  
 
Figure 4.3.7 Representative fluorescence intensity profiles of 40kDa dextran 
tagged with FITC in the rabbit eye in vivo over time after a suprachoroidal 
injection of 50 µL using a microneedle. Each profile was created from a single 
scan of the eye along the visual axis. The x-axis, position, represents the visual 
axis of the eye with the cornea located to the right of the x-axis in the anterior 
segment. The approximate position of eye tissues is estimated from baseline 






Figure 4.3.8 Representative fluorescence intensity profiles of 250kDa dextran 
tagged with FITC in the rabbit eye in vivo over time after a suprachoroidal 
injection of 50 µL using a microneedle. Each profile was created from a single 
scan of the eye along the visual axis. The x-axis, position, represents the visual 
axis of the eye with the cornea located to the right of the x-axis in the anterior 
segment. The approximate position of eye tissues is estimated from baseline 






Figure 4.3.9 Representative fluorescence intensity profiles of bevaciszumab 
tagged with Alexa Fluor 488 in the rabbit eye in vivo over time after a 
suprachoroidal injection of 50 µL using a microneedle. Each profile was created 
from a single scan of the eye along the visual axis. The x-axis, position, 
represents the visual axis of the eye with the cornea located to the right of the x-
axis in the anterior segment. The approximate position of eye tissues is 
estimated from baseline scans of the eye. The scans show that the peak intensity 







Figure 4.3.10 Average fluorescence intensity of 40 kDa dextran tagged with 
FITC in the suprachoroidal space over time after a suprachoroidal injection of 50 
µL using a microneedle. The fluorescence intensity drops over time and the 
dextran is cleared from the vitreous within 24 hours after injection. (n=2 and error 




Figure 4.3.11 Average fluorescence intensity of 250 kDa dextran tagged with 
FITC in the suprachoroidal space over time after a suprachoroidal injection of 50 
µL using a microneedle. The fluorescence intensity drops over time and the 
dextran is cleared from the vitreous in approximately 24 hours after injection. 






Figure 4.3.12 Average fluorescence intensity of bevacizumab tagged with Alexa 
Fluro 488 in the suprachoroidal space over time after a suprachoroidal injection 
of 50 µL using a microneedle. The fluorescence intensity drops over time and 
bevacizumab is cleared from the vitreous in approximately 24 hours after 
injection. (n=2 and error bars are standard deviations). 
 
 
4.3.4 Injection of Particles in to the Suprachoroidal Space 
 We hypothesize that particles could be injected into the suprachoroidal 
space of rabbit eyes in vivo with similar targeting to the chorioretinal tissues as 
molecules. We further believe that particles will have a longer residence time 
than molecules injected into the space and thus can be used for sustained 
delivery. In order to test this hypothesis we injected non degradable fluorescent 
particles, FluoSpheres®, into the suprachoroidal space using a hollow 
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microneedle. These particles are designed not to leach the fluorescent dye from 
within the particle. As a result fluorescence scans in the eye after injection  will 
reveal  the presence of the particles and not the release of the fluorescent dye 
within the particle.  Four particle sizes were injected into the suprachoroidal 
space: 20 nm, 500 nm, 1 µm and 10 µm in diameter.  
Fluorescence intensity scans in the eye show that particles can be 
selectively injected into the suprachoroidal space of rabbit eyes (Figure 4.3.13 
and 4.3.14). All eyes injected with particles showed an increase in fluorescence 
intensity within the suprachoroidal space within minutes after injection. The peak 
fluorescent intensity within each profile was located in the suprachoroidal space 
at all time points. The fluorescence intensity dropped off quickly in the 
surrounding tissues indicating that the particles had not significantly migrated into 
surrounding tissues. All particle injections within the suprachoroidal space 
exhibited the same profile shape.  The particles were also well targeted to the 
back of the eye. Performing a similar analysis to the fluorescein injections, the 
ratio of fluorescence intensity in the suprachoroidal space to that near the lens 
was determined and it showed that for all scans the ratio was above 10 for the 
time periods tested. This indicates that the particles were present in the 
suprachoroidal space throughout this time period and were well targeted to the 
chorioretinal tissues.  
 





Figure 4.3.13 Representative fluorescence intensity profiles of 20 nm particles in 
the rabbit eye in vivo over time after a suprachoroidal injection of 50 µL using a 
microneedle. Each profile was created from a single scan of the eye along the 
visual axis. The x-axis, position, represents the visual axis of the eye with the 
cornea located to the right of the x-axis in the anterior segment. The approximate 
position of eye tissues is estimated from baseline scans of the eye. The scans 
show that the peak intensity remains in the suprachoroidal space and does not 






Figure 4.3.14 Representative fluorescence intensity profiles of 500 nm particles 
in the rabbit eye in vivo over time after a suprachoroidal injection of 50 µL using a 
microneedle. Each profile was created from a single scan of the eye along the 
visual axis. The x-axis, position, represents the visual axis of the eye with the 
cornea located to the right of the x-axis in the anterior segment. The approximate 
position of eye tissues is estimated from baseline scans of the eye. The scans 
show that the peak intensity remains in the suprachoroidal space and does not 
return to baseline in the time tested. 
  
 In order to determine if the particles were being cleared from the 
suprachoroidal space, the peak fluorescence intensity within the suprachoroidal 
space was determined over time for each particle size (Figures 4.3.15 and 
4.3.16). The average fluorescence intensity within the suprachoroidal space was 
plotted over time for each particle size. Rabbits injected with 20 nm particles 
were followed for 35 days and rabbits injected with 500 nm particles were 
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followed for 28 days. All rabbits maintained fluorescence intensity levels within 
suprachoroidal similar to levels obtained immediately following the 
suprachoroidal injection. Statistical analysis (ANOVA p<0.05) revealed that all 
readings were similar indicating that over time the particles were not being 
cleared from the suprachoroidal space. Rabbits injected with 1 and 10 µm were 
followed for 60+ days. A plot of the fluorescence intensity over time reveals that 
the fluorescence intensity also does not drop over the time period tested 
(ANOVA p<0.05). This indicates that all 4 particles, once injected into the 
suprachoroidal space, remain in the suprachoroidal space for at least the time 





Figure 4.3.15 Average fluorescence intensity of 20 and 500 nm particles in the 
suprachoroidal space over time after a suprachoroidal injection of 50 µL using a 
microneedle. The fluorescence intensity does not drop over the time tested 
(ANOVA p<0.05) indicating the particles are still present in the suprachoroidal 





Figure 4.3.16 Average fluorescence intensity of 1 and 10 µm particles in the 
suprachoroidal space over time after a suprachoroidal injection of 100 µL using a 
microneedle. The fluorescence intensity does not drop over the time tested 
(ANOVA p<0.05) indicating the particles are still present in the suprachoroidal 
space in a similar concentration to the initial amount. (n=2 and error bars are 
standard deviations). 
 
In order to visually confirm the presence of the particles in the eye, in vivo 
fundus imaging as well as histological examination was performed. Fundus 
photography was performed on rabbits injected with one and ten micrometer 
 123
particles (Figure 4.3.17). The fundus of the injected eyes appeared normal with 
no inflammation or abnormalities as compared to an uninjected eye (Figure 
4.3.17 a,c,e). Fluorescence images of the fundus revealed that the particles were 
distributed throughout the back of the eye and had reached as far back as the 
optic nerve (Figure 4.3.17 b,d,f). The fluorescence images of the fundus also 
show that there are particles behind the chroriodal blood vessels as the blood 
vessels block some of the fluorescence. This confirms that even after 60 days 
the particles are still present. This also shows that there are still particles in the 
suprachoroidal space and they have not diffused into the vitreous. In order to 
confirm the exact location of the particles histological examination of the tissues 
was performed after enucleation of the eyes at the end of the study. Figure 
4.3.18 shows a cross section of the rabbit tissue 28 days after injection of 500 
nm particles into the suprachoroidal space. The bright fluorescence seen in the 
image is the 500 nm particles in the suprachoroidal space. This image confirms 
that the particles are still present even after 28 days and are well localized in the 
suprachoroidal space. Figure 4.3.19 shows a cross section of rabbit tissue 60+ 
days after injection of 1 and 10 µm particles. The particles are well localized to 
the suprachoroidal space and do not even appear in the retina. These data 
visually confirm the presence of particles in the suprachoroidal space and 







Figure 4.3.17 Fundus photography of rabbit eyes injected with (a,b) 1 µm and 
(c,d) 10 µm particles in the suprachoroidal space and with (e,f) no injection. 
Images a, c, and e are color fundus images that show the ocular anatomy while 
b, d, and f are fluorescence images of the fundus that show the location of 
fluorescent particles. Arrows indicate the location of the optic cup. The bright 




Figure 4.3.18 Cross-section of rabbit eye tissue 28 days after a suprachoroidal 
injection of 500 nm particles in a rabbit eye in vivo. The arrow points to 
fluorescent particles in the suprachoroidal space. This confirms that the particles 








Figure 4.3.19 Cross-section of rabbit eye tissue approximately 60 days after a 
suprachoroidal injection of (a) 1 µm and (b) 10 µm particles in a rabbit eye in 
vivo. The arrows points to fluorescent particles in the suprachoroidal/choroidal 
space. The sclera (S) and the choroid (C) can be seen with portions of the retina 
(R). This confirms that the particles are still present in the suprachoroidal space 
even after 60 days. Scale bar: 500 µm. 
 
 
4.3.5 Discussion  
  In this study we investigated for the first time the intraocular kinetics of 
materials injected into the suprachoroidal space. This work represents the first 
comprehensive study to examine the administration of small molecules, 
macromolecules, nanoparticles and microparticles into the suprachoroidal space. 
The work also shows for the first time that a hollow microneedle can inject a 
variety of materials into the suprachoroidal space of an eye in vivo. This work first 
characterized the intraocular concentration profile of a suprachoroidal injection 
and compared it to an intravitreal injection profile using sodium fluorescein as a 
model compound. This data showed that suprachoroidal injections were more 
effective at targeting the chorioretinal tissues than intravitreal injections. The 
study further compared the half lives of both injection methods and determined 
them both to be very quick, less than 3 hours for each. We further showed that 
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microneedles could inject macromolecules, including a therapeutic antibody, into 
the suprachoroidal space. An important result of this study is that it showed 
nano- and microparticles could be injected into the suprachoroidal space using a 
microneedle and were not cleared from the eye for at least 2 months.  
  In vivo fluorescence measurements were used in this study to determine 
the levels of the injected molecules in the eye. This method offers a non invasive 
way to measure fluorescence intensities in both the front and back of the eye in 
real time. As a result, the relative amounts of an injected molecule can be 
monitored in its normal state since no anesthesia is necessary to perform the 
scan. One of the biggest advantage is this approach allows longitudinal studies 
of fluorescent intensities in a single dimension in the eye. One of the limitations is 
that only a small region of the eye can be measured in any given scan and 
movement of molecules outside of this one dimensions will not be captured from 
this type of approach.  A scan will not be able to capture what is occurring in the 
extreme periphery of the eye since the light beam will not penetrate through the 
pupil at angles that are not nearly perpendicular to the ocular surface. When the 
animal is not under the influence of anesthesia the animal is also free to move its 
eye and the exact spot being measured will vary from scan to scan. Additionally, 
this requires the molecule to be fluorescent or needs to be tagged with a 
fluorophore with excitation and emission wavelengths in the range that is 
detectable by the Fluorotron. This limits the type of molecules that can be tested 
and also means the doses that can be tested are dependent on the resolution of 
the fluorophore on the machine. Even with these limitations this approach offers 
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a unique way to quickly monitor the levels in the eye of an animal over time in a 
non invasive way and can help show the one dimensional distribution of an 
injected molecule.  
  The results from this study show that molecules injected into the 
suprachoroidal space are removed from this space within a 24 hour timeframe. 
This is true for a small molecule such as fluorescein as well as large 
macromolecules such as dextrans and bevascizumab. The mechanisms 
responsible for this clearance are uncertain and detailed studies for determining 
these mechanisms are still necessary. However, there may be two main 
mechanisms responsible for transport of these molecules from this space. One 
mechanism may be the transport of molecules facilitated by uveal scleral outflow 
pathway. Some aqueous humor is naturally removed from the anterior segment 
of the eye through flow into the suprachoroidal space and subsequently out of 
the eye through the sclera (Alm and Nilsson 2009). This bulk flow may also 
contribute to the transport of injected molecules directly into the suprachoroidal 
space.  A second mechanism that may be responsible for clearance of molecules 
is uptake of the molecules into the choroidal blood vessels. The injection is in 
direct contact with the choroidal blood vessels and molecules may be absorbed 
into the blood circulation and carried away from the eye. The role these 
mechanisms play may be better addressed with actual pharmacokinetic 
experiments analyzing tissue concentrations within the eye and blood levels of 
various molecules. Fluorophotometry may not be the best way to study this 
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phenomena since it only provides a one dimensional view to a three dimensional 
problem with dynamic clearance pathways.  
Particles injected into the suprachoroidal space do not appear to be easily 
cleared from this space. For the time period tested, the size of the particles did 
not influence the residence time. There may not be an active mechanism to take 
up the nano- and microparticles injected into the suprachoroidal space. Diffusion 
of particles into the surrounding region may not be possible because of barriers 
such as the retinal pigment epithelium and sclera that do not easily allow large 
particles to migrate through. Uptake of these particles in to the choroidal blood 
vessels may also not be occurring. As a result both nano- and microparticles 
remain in the suprachoroidal space. In order to determine what factors of the 
particles cause them to remain in the suprachoroidal space much longer than 
small and large molecules, further studies would need to be performed using 
particles made of different sizes, materials and chemistries.  
What this study does show, is that there may be a way to provide 
sustained delivery from within the suprachoroidal space. There are materials that 
will be cleared from the suprachoroidal space on a time scale of hours (soluble 
molecules) and there are also materials that will remain in the space for months 
(particles). Using this understanding, it may be possible for degradable particles 
to provide sustained delivery from within the suprachoroidal space. If degradable 
particles loaded with a drug are injected within this space they can remain in this 
space for months. As the particles degrade their degradation products and drug 
will be released into the suprachoroidal space. The study of macromolecules 
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demonstrates that the degradation products can be cleared from the space. At 
the same time, the drug can be released into the suprachoroidal space to provide 
sustained release to the surrounding tissues.  This ensures that once the 
particles completely broken down there is a mechanism for their degradation 
products to be cleared from within this space and the site can be redosed.  
 
4.3.6 Conclusion  
 This study demonstrated that small and large molecules can be injected 
into the suprachoroidal space of live rabbits. In addition this was the first work to 
examine the clearance kinetics of a variety of materials from within the 
suprachoroidal space. The study showed that the clearance kinetics of soluble 
molecules is relatively fast, occurring on the order of hours. As a result drug 
solutions injected into the suprachoroidal space may not be ideal for sustained 
delivery to the suprachoroidal space. However, fluorescent nano- and 
microparticles injected into this space were present for up to two months within 
the suprachoroidal space with no appreciable drop off in fluorescent intensity. 
Particles may be an ideal way to provide sustained delivery from within the 
suprachoroidal space to the surrounding tissues.  
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CHAPTER 5  
CONCLUSION 
Delivering drugs effectively to the eye is a challenging task. One of the 
most challenging aspects of drug delivery to the eye is to target the delivery to 
the diseased tissues. In the case of posterior segment diseases, such as age 
related macular degeneration (AMD), drugs need to reach the choroid and retina 
(chorioretinal tissues) to provide a therapeutic effect. Although there are a 
number of drugs that have been shown to be effective at treating diseases of the 
choroid and retina, there are very few delivery methods that can target and 
localize the drug to these tissues. Most delivery methods aim to inject a drug into 
the vitreous or on the extraocular surface of the globe. Although these can be 
designed to provide sustained delivery for periods of months to years, they are 
still not able effectively target the drug to the chorioretinal tissues without 
exposing other parts of the eye to the drug. The research presented in this thesis 
demonstrates a novel alternative to the current approaches to drug delivery to 
the eye.  
This first part of the work introduced our minimally invasive strategy for 
drug delivery to the back of the eye. It showed that a hollow microneedle can be 
inserted into the sclera and inject liquid solutions and suspension of particles into 
the suprachoroidal space of rabbit, pig and human eyes ex vivo. The 
suprachoroidal space is a virtual space that is located between the sclera and 
choroid layers of the eye. This demonstrated that the injection spreads 
circumferentially around the eye within the suprachoroidal space.  We showed 
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that by optimizing parameters such as infusion pressure and microneedle length, 
particles are reliably delivered into the suprachoroidal space. As a result, these 
data could be used to design an effective device for delivering drug formulations 
into the eye.  
Armed with this information, the second part of the study developed an in 
vivo device for injection into rabbit eyes. This device was shown to reliably inject 
India ink into the suprachoroidal space. This study represents the first study to 
examine the capability of a hollow microneedle to inject within the suprachoroidal 
space of a live animal eye.  The India ink study also showed that volumes up to 
100 µL could be delivered into the rabbit eye and the India ink is well localized to 
the suprachoroidal space. This device allowed us to study the coverage of the 
chorioretinal surface.  We were able to show that suprachoroidal injections of 
India ink cover up to 36 % of the available surface a single microneedle injection 
of 100 µL. Further characterization of the spread showed the India ink reaches 
the optic nerve in the back of the eye with a volume as small as 30 µL and further 
injections do not cause the spread to occur further back but instead in the lateral 
direction around the eye. In addition, the analysis showed that volumes in excess 
of 50 µL can cause the suprachoroidal space to expand in thickness and these 
thicknesses are on the order of several hundred micrometers.  
 In addition we developed a hollow metal microneedle that could be easily 
attached to a syringe to make a simple injection device. We showed that with this 
metal hollow microneedle device we could inject latex within the suprachoroidal 
space of fresh human cadaver eyes. The work showed that it was possible to 
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inject up to 150 µL of latex in to the suprachoroidal space and cover up to 40 % 
of the chorioretinal surface. In addition, the injections were performed at a site 
that would be accessible on a human (8 mm posterior to the limbus) and the 
results show that it is possible to inject in the suprachoroidal space from such a 
site.  In addition the volumes injected represent volumes that are currently being 
injected into the vitreous for treatment of diseases such as AMD. As a result, this 
shows that it would be theoretically possibly to inject a comparable dose into the 
suprachoroidal space.  
 The final leg of the study, examined the intraocular pharmacokinetics of 
materials injected into the suprachoroidal space of rabbits in vivo. This work 
represents the first comprehensive study to examine the administration of small 
molecules, macromolecules, nanoparticles and microparticles into the 
suprachoroidal space. We were able to characterize the intraocular concentration 
profile of a suprachoroidal injection and compare it to an intravitreal injection 
profile using sodium fluorescein as a model compound. This data showed that 
suprachoroidal injections were more effective at targeting the chorioretinal 
tissues than intravitreal injections. The study further compared the half lives of 
both injection methods and determined them both to be very fast, less than 3 
hours for each. We further showed that microneedles could inject 
macromolecules, including a therapeutic antibody, into the suprachoroidal space. 
An important result of this study is that it showed nano- and microparticles could 
be injected into the suprachoroidal space using a microneedle and were not 
cleared from the eye for at least 2 months.  
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Suprachoroidal delivery represents an improvement over current 
periocular and intravitreal delivery methods, both of which are poorly targeted to 
the chorioretinal tissues affected by posterior segment diseases. Rather than 
injecting drug outside the eye or in the vitreous humor, microneedle technology 
enables precisely targeted injection within the suprachoroidal space of the ocular 
tunic, which bathes the chorioretinal surface with the drug formulation. Moreover, 
by taking advantage of the unique features of ocular anatomy, a microneedle 
injection does not expose the drug formulation to many tissues as do 
conventional injections. Instead, by targeting the suprachoroidal space, the drug 
formulation infuses circumferentially within the suprachoroidal space to cover the 
chorioretinal surface from a single injection. 
This method of delivery has four important attributes of an effective drug 
delivery system for the posterior segment. First, the use of a hollow microneedle 
allows the delivery method to be minimally invasive, because the microneedle 
only penetrates hundreds of micrometers into the eye, which should protect the 
retina from mechanical damage and reduce the risk of infection.  We showed 
with our in vivo rabbit studies that the injections could be performed without any 
significant surgery and can be done quickly. This is a significant improvement 
over past studies that have accessed the suprachoroidal space using much more 
invasive procedures (Einmahl et al 2002, Gilger et al 2006, Olsen et al 2006, Kim 
et al 2007). As a result, this may offer a safety and convenience advantage.   
Second, the suprachoroidal space offers the ability to target the choroid 
and retina by localizing the injection immediately adjacent to these tissues. Our 
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kinetic study showed that the intraocular concentration profiles of all materials 
injected into the suprachoroidal space were better targeted to chorioretinal 
tissues as compared to the conventional intraviteral injection. Suprachoroidal 
injections maintained this targeting through the time the material was in the eye. 
Third, we showed the potential for sustained delivery by demonstrating injection 
of particles up to 10 µm diameter into the suprachoroidal space of rabbits in vivo. 
The ability of the suprachoroidal space to accommodate particles has not been 
previously reported. Our findings suggest that particles can remain in the 
suprachoroidal space for a period of months. This opens up the possibility of 
injecting drug-loaded biodegradable particles into the suprachoroidal space for 
sustained drug release over a period of weeks to months, which could reduce the 
frequency of drug administration. Finally, with the inherent simplicity of the 
microneedle injection and with a properly designed microneedle device, 
suprachoroidal delivery could be carried out as a straightforward office procedure 
rather than a surgical one. 
Overall this work shows that suprachoroidal drug delivery is a viable new 
route of administration for the treatment of chorioretinal diseases. Furthermore, 
administration using a microneedle based device could make the device simple 
and minimally invasive.     
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CHAPTER 6  
DISCUSSION AND RECOMMENDATIONS 
 The research presented here represents some of the first studies to 
examine the suprachoroidal space as a local drug delivery route for the eye. This 
work also represents the first attempt to use microneedles as a way to administer 
fluids and particles into this space. The results from this work show that this is a 
promising route of delivery for treating diseases of the eye. However, there are 
still many unanswered questions and theories that need exploring before the full 
potential of this strategy can be understood.  
   We have shown with the prototype devices that we can reliably deliver 
materials into the suprachoroidal space of rabbits in vivo and within human 
cadaver eyes. However, in order to test this type of delivery on humans, 
improvement of the device and method need to be addressed. In order to 
decrease the risk of improper delivery, the insertion of the microneedles should 
be properly done to access the suprachoroidal space. The device or method 
should allow the microneedle to reach as close as possible to the suprachoroidal 
space without penetrating into the choroid. This would allow the best chance of 
targeting the space. This could be accomplished by measuring the thickness of 
the patient’s sclera and conjunctiva and then choosing a proper sized 
microneedle. An alternative would be to incorporate a feedback system within the 
insertion device to allow for proper positioning. Our work also showed that the 
infusion pressure was important. As a result, the device should allow for proper 
 137
control of infusion pressure. The device should prioritize safety and minimize 
trauma to the eye from both the insertion and the infusion.  
 Future work also needs to focus on understanding the intraocular 
pharmacokinetics of suprachoroidal injections. Experiments should be designed 
to understand how formulation changes and properties of molecules influence 
the pharmacokinetics within the eye. Lipophilic drugs, such as steroids, may 
have prolonged residence times because of their low solubility in aqueous 
environments. In addition, formulation changes may allow for tuning of clearance 
rates as well as spread within the suprachoroidal space. Gel formulations may 
provide slower release of drugs as well as unique spread profiles within the 
suprachoroidal space. As an example, if a formulation can be designed so as to 
limit spread of the injection just around the limbus, this formulation may have 
applications in glaucoma therapy. In addition, biodegradable particles with 
encapsulated drugs need to be evaluated within the suprachoroidal space to 
demonstrate sustained release.  Understanding this and determining the 
concentration of drugs in the intraocular tissues will help determine the potential 
of these injections have to treat diseases.  
 In addition to pharmacokinetics, pharmacotherapy from within this space 
also needs to be evaluated. The potential to actually treat diseases from within 
this space still needs to be proven. One of the first things is to determine what 
diseases can actually be treated. Diseases of the choroid and retina appear to be 
the most relevant. Animal models of these diseases could be used to evaluate 
the potential to treat these diseases from suprachoroidal delivery. Furthermore, 
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the targeting to chorioretinal tissues enabled by this delivery might enable a 
preventative approach to treating diseases. As an example, choroidal 
neovascularization, is a major component of advanced AMD and anti-VEGF 
therapies do exist to treat neovascularization. Based on the proposed 
mechanisms for the disease, if antibodies against neovascularization can be 
delivered to the choroid it may prevent the blood vessels from growing and 
damaging the retina. Since suprachoroidal injections can deliver drugs directly to 
the choroid, injecting these antibodies during the early progression of the disease 
may prevent damage to the retina.  
 An evaluation of the safety from these types of injections will also be an 
important area to study if suprachoroidal injections are to be used on humans. 
This applies to not just the safety of the injection, but also the safety of drugs and 
fluids occupying the space for an extended period of time. Some of the critical 
things to examine are if there is any serious complication, edema, inflammation, 
abnormal vessel growth, or deterioration of visual function as a result of the 
injection. Formulations within the space may affect some of the natural 
processes in the eye, such as uveal scleral outflow. The effect of repeated 
injections in to the space also needs to be characterized. This is especially 
important since the patients being treated already have compromised ocular 
integrity.  
 In the context of ocular drug delivery, this work offers an exciting 
opportunity to explore a new strategy enabled by microneedle technology. It 
demonstrates that it may be possible to provided targeted, minimally invasive 
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and sustained drug delivery from a single device. From a research perspective 
there is a lot that can be learned by exploring this route and comparing it to the 
options that are currently available. It may serve as a research tool that can lead 
to the discovery of new drugs. It may also lead to optimized formulations for 
applications in the suprachoroidal space in the eye. We hope this work will lead 
to new research to explore the benefits of targeting in ocular drug delivery. We 
are optimistic that this work will play an important role in developing better 
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